RNA-based therapeutics: an overview and prospectus

The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto “undruggable” proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been appr...

Full description

Saved in:
Bibliographic Details
Published in:Cell death & disease Vol. 13; no. 7; pp. 644 - 15
Main Authors: Zhu, Yiran, Zhu, Liyuan, Wang, Xian, Jin, Hongchuan
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 23.07.2022
Springer Nature B.V
Nature Publishing Group
Subjects:
38/71
38/90
42/89
45/91
631/154/152
631/61/391/1914
64/60
Antibodies
Binding sites
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Culture
Clinical trials
Disease
Drugs
Enzymes
Gene expression
Genomes
Immunology
Life Sciences
Medical research
MicroRNAs
Proteins
Review
Review Article
Ribonucleic acid
RNA
RNA Interference
RNA, Small Interfering - genetics
Therapeutic targets
ISSN:2041-4889, 2041-4889
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto “undruggable” proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.
AbstractList The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto “undruggable” proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.
Abstract The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto “undruggable” proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.
The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto "undruggable" proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto "undruggable" proteins, transcripts and genes, thus potentially broadening the therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques have been explored to promote RNA intracellular trafficking and metabolic stability, despite significant challenges in developing RNA-based therapeutics. In this review, the mechanisms of action, challenges, solutions, and clinical application of RNA-based therapeutics have been comprehensively summarized.
ArticleNumber 644
Author Jin, Hongchuan
Zhu, Yiran
Wang, Xian
Zhu, Liyuan
Author_xml – sequence: 1
  givenname: Yiran
  surname: Zhu
  fullname: Zhu, Yiran
  organization: Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 2
  givenname: Liyuan
  surname: Zhu
  fullname: Zhu, Liyuan
  organization: Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 3
  givenname: Xian
  surname: Wang
  fullname: Wang, Xian
  organization: Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
– sequence: 4
  givenname: Hongchuan
  orcidid: 0000-0002-6697-3097
  surname: Jin
  fullname: Jin, Hongchuan
  email: jinhc@zju.edu.cn
  organization: Laboratory of Cancer Biology, Key Lab of Biotherapy in Zhejiang Province, Cancer Center of Zhejiang University, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35871216$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhS3Uipahf4AFGokNm1A_Y5sFUlW1UKkCCcHacuybqUeZONjJIP49nknfi3rjK99zPh1d3zfooI89IPSO4E8EM3WaOeFEV5jSCgssRUVfoWOKOam4UvrgUX2ETnJe43IYw1TUr9ERE0oSSupjRH9-P6sam8EvxxtIdoBpDC5_Xtp-GbeQtgH-ltovhxTzAG6c8lt02Nouw8ntvUC_Ly9-nX-rrn98vTo_u65cjeux8t474hz3zEmtgDTOc2rbRnDZgPAltPVCCc5bVTrSgvQNBdny1ilOQLEFupq5Ptq1GVLY2PTPRBvM_iGmlbGphO3ACM-UF1gT4TVnxCqmGRAHwLBTrRCF9WVmDVOzAe-gH5PtnkCfdvpwY1ZxazTDChfaAn28BaT4Z4I8mk3IDrrO9hCnbGitmZREqJ30wzPpOk6pL6Paq4gStSZF9f5xovsod19TBGoWuDL5nKA1Lox2DHEXMHSGYLNbBDMvgimLYPaLYGix0mfWO_qLJjabchH3K0gPsV9w_Qcl28R5
CitedBy_id crossref_primary_10_1002_adfm_202312260
crossref_primary_10_1016_j_ijbiomac_2023_124582
crossref_primary_10_3390_molecules28166015
crossref_primary_10_1016_j_gene_2024_148975
crossref_primary_10_1016_j_chroma_2023_464184
crossref_primary_10_1080_21541264_2023_2294623
crossref_primary_10_3390_biomedicines10123066
crossref_primary_10_1111_cns_14763
crossref_primary_10_1002_adhm_202401466
crossref_primary_10_1126_sciadv_adv9571
crossref_primary_10_3390_biom14040477
crossref_primary_10_1016_j_anai_2024_04_029
crossref_primary_10_3390_medsci12020028
crossref_primary_10_1080_20415990_2024_2400044
crossref_primary_10_3389_fbioe_2023_1244377
crossref_primary_10_1016_j_ijcrp_2024_200323
crossref_primary_10_1016_j_ymthe_2023_01_005
crossref_primary_10_1038_s12276_023_00998_y
crossref_primary_10_1007_s40265_025_02173_1
crossref_primary_10_1042_BST20253041
crossref_primary_10_1111_ejh_14313
crossref_primary_10_3390_pharmaceutics17070899
crossref_primary_10_1016_j_omtn_2025_102453
crossref_primary_10_1161_CIRCULATIONAHA_123_067373
crossref_primary_10_1016_j_str_2024_08_015
crossref_primary_10_1038_s41418_024_01332_3
crossref_primary_10_1016_j_mcn_2025_104010
crossref_primary_10_3390_ijms241310674
crossref_primary_10_1016_j_nbd_2024_106456
crossref_primary_10_3390_ijms252413488
crossref_primary_10_1002_cmdc_202400111
crossref_primary_10_3390_ijms25147612
crossref_primary_10_3389_fgene_2025_1603498
crossref_primary_10_1021_acs_jpclett_5c02341
crossref_primary_10_1093_nar_gkad807
crossref_primary_10_7554_eLife_89136
crossref_primary_10_1002_advs_202414961
crossref_primary_10_1016_j_fmre_2023_07_001
crossref_primary_10_1016_j_ijbiomac_2025_141002
crossref_primary_10_1007_s12013_024_01423_5
crossref_primary_10_1002_anie_202302676
crossref_primary_10_1016_j_molcel_2023_11_041
crossref_primary_10_1002_ijch_202300169
crossref_primary_10_1016_j_omtn_2023_07_009
crossref_primary_10_1080_17576180_2024_2437418
crossref_primary_10_1016_j_cej_2025_165777
crossref_primary_10_1111_ejn_70110
crossref_primary_10_3390_biology14091265
crossref_primary_10_1093_nar_gkac1147
crossref_primary_10_1007_s40843_024_3048_0
crossref_primary_10_1038_s41587_023_02105_y
crossref_primary_10_1093_nar_gkae1117
crossref_primary_10_1016_j_jconrel_2024_04_003
crossref_primary_10_1016_j_tips_2025_05_006
crossref_primary_10_3390_nano13121828
crossref_primary_10_1016_j_ejps_2024_106981
crossref_primary_10_1016_j_heliyon_2024_e31276
crossref_primary_10_1016_j_omtn_2024_102195
crossref_primary_10_3390_molecules27196717
crossref_primary_10_1016_j_chroma_2024_465412
crossref_primary_10_1007_s42764_024_00135_7
crossref_primary_10_1016_j_phrs_2024_107469
crossref_primary_10_37349_emd_2025_1007103
crossref_primary_10_3390_ijms25020761
crossref_primary_10_1021_acs_jcim_5c00205
crossref_primary_10_3390_ph18070987
crossref_primary_10_1016_j_stemcr_2025_102603
crossref_primary_10_1021_acs_analchem_4c05968
crossref_primary_10_3390_pharmaceutics17010110
crossref_primary_10_1002_adfm_202314088
crossref_primary_10_1016_j_phrs_2023_106870
crossref_primary_10_1007_s12272_022_01418_x
crossref_primary_10_1038_s41587_024_02336_7
crossref_primary_10_1016_j_bbagrm_2023_194990
crossref_primary_10_1186_s12935_025_03868_x
crossref_primary_10_1093_bioinformatics_btaf203
crossref_primary_10_1002_adtp_202500082
crossref_primary_10_3390_life15010095
crossref_primary_10_1002_iid3_70200
crossref_primary_10_1016_j_ymthe_2023_12_009
crossref_primary_10_3390_jpm13111586
crossref_primary_10_1002_adfm_202311920
crossref_primary_10_1186_s13046_023_02725_x
crossref_primary_10_1016_j_ejmech_2025_117682
crossref_primary_10_1016_j_jddst_2025_106816
crossref_primary_10_1186_s13046_025_03391_x
crossref_primary_10_1039_D4NR03159H
crossref_primary_10_1016_j_bcp_2024_116107
crossref_primary_10_3390_cancers17091485
crossref_primary_10_1038_s41551_025_01429_1
crossref_primary_10_1039_D5SC05255F
crossref_primary_10_1016_j_pharmthera_2024_108774
crossref_primary_10_1007_s12079_023_00746_x
crossref_primary_10_1016_j_cpcardiol_2024_102419
crossref_primary_10_1016_j_compbiomed_2025_109663
crossref_primary_10_1002_cmdc_202300271
crossref_primary_10_1002_advs_202503534
crossref_primary_10_1007_s12274_024_6575_8
crossref_primary_10_1093_bib_bbad186
crossref_primary_10_3390_pharmaceutics16111379
crossref_primary_10_1111_bph_16424
crossref_primary_10_1016_j_jiac_2024_08_015
crossref_primary_10_1002_adhm_202500605
crossref_primary_10_1016_j_addr_2025_115685
crossref_primary_10_1016_j_chembiol_2024_08_009
crossref_primary_10_1021_acsabm_4c01319
crossref_primary_10_1038_s41467_025_59947_0
crossref_primary_10_1038_s41467_025_62607_y
crossref_primary_10_1007_s40119_024_00353_w
crossref_primary_10_1192_bja_2023_55
crossref_primary_10_3390_pharmaceutics16040482
crossref_primary_10_1021_acs_nanolett_5c01254
crossref_primary_10_20935_AcadBiol7599
crossref_primary_10_1016_j_cpcardiol_2024_102627
crossref_primary_10_4155_bio_2024_0007
crossref_primary_10_3390_pharmaceutics16111366
crossref_primary_10_1002_adhm_202402933
crossref_primary_10_1016_j_pcad_2024_01_016
crossref_primary_10_1093_nargab_lqae048
crossref_primary_10_3390_ijms252312883
crossref_primary_10_1016_j_cbi_2024_110965
crossref_primary_10_1080_08923973_2024_2391471
crossref_primary_10_1111_febs_17368
crossref_primary_10_1038_s41422_024_00975_8
crossref_primary_10_1016_j_xinn_2025_101011
crossref_primary_10_3390_biom15040468
crossref_primary_10_1002_adma_202401640
crossref_primary_10_1007_s00210_025_04404_4
crossref_primary_10_1016_j_omtm_2025_101505
crossref_primary_10_3390_jpm13040664
crossref_primary_10_1016_j_bioactmat_2025_09_007
crossref_primary_10_1016_j_addr_2024_115291
crossref_primary_10_1016_j_cbpa_2024_102479
crossref_primary_10_1016_j_drudis_2025_104366
crossref_primary_10_1016_j_genrep_2022_101676
crossref_primary_10_1016_j_rechem_2025_102305
crossref_primary_10_1038_s41419_023_05695_2
crossref_primary_10_3390_ijms26010110
crossref_primary_10_7554_eLife_97487
crossref_primary_10_1007_s40259_024_00644_7
crossref_primary_10_1038_s41467_024_45968_8
crossref_primary_10_1016_j_meegid_2024_105613
crossref_primary_10_1016_j_tibtech_2024_07_010
crossref_primary_10_3390_cells12192398
crossref_primary_10_3390_ijms242316933
crossref_primary_10_3390_biology12091232
crossref_primary_10_3390_cancers17030472
crossref_primary_10_5812_zjrms_161252
crossref_primary_10_1186_s12885_025_14356_w
crossref_primary_10_1080_17460441_2023_2244409
crossref_primary_10_3390_insects13110968
crossref_primary_10_1016_j_addr_2024_115283
crossref_primary_10_1016_j_cclet_2024_110225
crossref_primary_10_1016_j_omtn_2025_102684
crossref_primary_10_3389_fcell_2025_1520850
crossref_primary_10_1088_1674_1056_adea9b
crossref_primary_10_1016_j_jmb_2024_168552
crossref_primary_10_1016_j_molp_2025_06_011
crossref_primary_10_1016_j_ijpx_2024_100283
crossref_primary_10_1021_jacs_3c00841
crossref_primary_10_3390_genes16010048
crossref_primary_10_3389_fphar_2022_1056467
crossref_primary_10_1186_s12951_024_02600_7
crossref_primary_10_1016_j_bcp_2025_117192
crossref_primary_10_1016_j_addr_2023_114826
crossref_primary_10_1007_s11033_024_09576_5
crossref_primary_10_1016_j_xphs_2024_09_015
crossref_primary_10_1007_s12010_023_04597_5
crossref_primary_10_1016_j_ymthe_2024_01_005
crossref_primary_10_1021_acs_chemrev_4c00482
crossref_primary_10_1016_j_addr_2024_115198
crossref_primary_10_1038_s41598_024_67797_x
crossref_primary_10_1016_j_chroma_2024_464862
crossref_primary_10_3390_antibiotics12040729
crossref_primary_10_1039_D5TB00117J
crossref_primary_10_1186_s12915_023_01731_x
crossref_primary_10_3389_fgene_2023_1281538
crossref_primary_10_1016_j_prp_2024_155769
crossref_primary_10_1016_j_molcel_2024_09_016
crossref_primary_10_1016_j_omtn_2024_102208
crossref_primary_10_1080_17435889_2025_2534326
crossref_primary_10_1016_j_bbagrm_2025_195091
crossref_primary_10_1007_s11095_025_03829_z
crossref_primary_10_1038_s41467_024_47444_9
crossref_primary_10_3390_jnt6020010
crossref_primary_10_7554_eLife_89136_3
crossref_primary_10_1007_s11033_024_09457_x
crossref_primary_10_1002_advs_202205713
crossref_primary_10_1073_pnas_2422085122
crossref_primary_10_1111_os_13851
crossref_primary_10_3390_biomedicines12030570
crossref_primary_10_3390_pharmaceutics17010058
crossref_primary_10_1021_acs_molpharmaceut_5c00670
crossref_primary_10_1177_21593337251377561
crossref_primary_10_4103_jpbs_jpbs_583_25
crossref_primary_10_3390_pharmaceutics17010055
crossref_primary_10_1021_acs_jcim_5c00814
crossref_primary_10_3389_fgeed_2023_1034720
crossref_primary_10_1016_j_prp_2024_155612
crossref_primary_10_1088_2632_959X_add7f5
crossref_primary_10_1002_ctm2_70135
crossref_primary_10_1038_s41467_024_50395_w
crossref_primary_10_1042_BCJ20230234
crossref_primary_10_1089_genbio_2023_0045
crossref_primary_10_1016_j_gendis_2025_101652
crossref_primary_10_1093_nar_gkaf239
crossref_primary_10_61186_MCH_2025_1072
crossref_primary_10_1186_s12645_024_00256_4
crossref_primary_10_3390_pharmaceutics17060789
crossref_primary_10_1016_j_biopha_2024_117753
crossref_primary_10_1007_s00044_024_03293_1
crossref_primary_10_3390_pharmaceutics15071972
crossref_primary_10_1016_j_prp_2024_155170
crossref_primary_10_3390_ijms26094161
crossref_primary_10_1016_j_jconrel_2024_07_055
crossref_primary_10_1038_s41467_025_57792_9
crossref_primary_10_4103_ohbl_ohbl_17_24
crossref_primary_10_1016_j_chroma_2025_465687
crossref_primary_10_1080_13880209_2025_2498169
crossref_primary_10_1186_s12967_024_05554_4
crossref_primary_10_3389_fmolb_2024_1504876
crossref_primary_10_5501_wjv_v12_i5_242
crossref_primary_10_1016_j_bmc_2024_117825
crossref_primary_10_1016_j_tig_2024_04_009
crossref_primary_10_3389_fddev_2024_1416737
crossref_primary_10_1016_j_bej_2023_109213
crossref_primary_10_1016_j_canlet_2024_216734
crossref_primary_10_1016_j_phrs_2024_107195
crossref_primary_10_1038_s41573_025_01237_x
crossref_primary_10_3389_fimmu_2023_1127704
crossref_primary_10_3390_ijms24087650
crossref_primary_10_1002_advs_202207118
crossref_primary_10_1039_D3BM00732D
crossref_primary_10_3389_fphar_2024_1437071
crossref_primary_10_3389_fnano_2025_1475969
crossref_primary_10_1016_j_ijbiomac_2025_146970
crossref_primary_10_3390_jcm14155515
crossref_primary_10_1038_s41569_025_01168_5
crossref_primary_10_3233_JND_221601
crossref_primary_10_1016_j_cellimm_2025_104944
crossref_primary_10_1016_j_omtn_2024_102412
crossref_primary_10_1016_j_bmc_2024_117616
crossref_primary_10_3389_fbioe_2024_1499474
crossref_primary_10_1080_17474086_2025_2459259
crossref_primary_10_20517_evcna_2025_33
crossref_primary_10_1007_s00210_025_03872_y
crossref_primary_10_1016_j_aquaculture_2025_742753
crossref_primary_10_1002_mef2_60
crossref_primary_10_3390_genes14020314
crossref_primary_10_3390_molecules29061244
crossref_primary_10_1002_ange_202302676
crossref_primary_10_7554_eLife_97487_3
crossref_primary_10_1021_acsnano_4c11412
crossref_primary_10_3390_ijms252212284
crossref_primary_10_1016_j_tig_2024_09_006
crossref_primary_10_1016_j_lfs_2024_122953
crossref_primary_10_1097_MS9_0000000000001118
crossref_primary_10_1002_ardp_202400404
crossref_primary_10_1016_j_carbpol_2025_123581
crossref_primary_10_1038_s41573_023_00829_9
crossref_primary_10_1016_j_antiviral_2025_106142
crossref_primary_10_1002_adhm_202503281
crossref_primary_10_1038_s44222_024_00259_1
crossref_primary_10_1182_blood_2023020910
crossref_primary_10_1016_j_addr_2025_115606
crossref_primary_10_1016_j_ijbiomac_2025_139532
crossref_primary_10_3389_fcell_2024_1483843
crossref_primary_10_1021_acs_jctc_5c00757
crossref_primary_10_2147_IJN_S429279
crossref_primary_10_3390_cells13181550
crossref_primary_10_1016_j_ejmech_2025_117736
crossref_primary_10_1016_j_ijpharm_2024_124151
crossref_primary_10_1038_s41419_023_05989_5
crossref_primary_10_1016_j_jconrel_2023_09_032
crossref_primary_10_1038_s41598_024_74962_9
crossref_primary_10_1089_scd_2024_0061
crossref_primary_10_3390_biomedicines12071489
crossref_primary_10_1007_s12032_025_02934_8
crossref_primary_10_1038_s41573_025_01280_8
crossref_primary_10_3389_fmolb_2022_1044126
crossref_primary_10_1016_j_heliyon_2024_e34183
crossref_primary_10_1002_advs_202410908
crossref_primary_10_1016_j_omtn_2024_102313
crossref_primary_10_1016_j_nantod_2025_102740
crossref_primary_10_1016_j_dnarep_2025_103821
crossref_primary_10_3390_ijms25052464
crossref_primary_10_1016_j_tig_2024_01_001
crossref_primary_10_3389_fmicb_2024_1393646
crossref_primary_10_1093_eurheartj_ehaf041
crossref_primary_10_1186_s12929_023_00970_y
crossref_primary_10_1016_j_ymthe_2024_01_028
crossref_primary_10_1016_j_jmgm_2024_108839
crossref_primary_10_1016_j_ijbiomac_2024_139219
crossref_primary_10_1186_s12943_024_01955_7
crossref_primary_10_1021_acs_molpharmaceut_4c00871
crossref_primary_10_1107_S2059798325000592
crossref_primary_10_32604_or_2024_043987
crossref_primary_10_1021_jacs_3c09230
crossref_primary_10_1080_01652176_2024_2363626
crossref_primary_10_1016_j_omtn_2024_102303
crossref_primary_10_1186_s12929_024_01049_y
crossref_primary_10_3390_a18020067
crossref_primary_10_1186_s40035_025_00466_9
crossref_primary_10_1002_btm2_10662
crossref_primary_10_1128_spectrum_01537_24
crossref_primary_10_1002_nep3_43
crossref_primary_10_3389_fphar_2022_1108263
crossref_primary_10_1016_j_addr_2024_115448
crossref_primary_10_1016_j_jtha_2024_04_006
crossref_primary_10_1002_adem_202402289
crossref_primary_10_1038_s41467_025_59885_x
crossref_primary_10_1080_15257770_2025_2451377
Cites_doi 10.1002/anie.201506030
10.1016/j.addr.2009.08.004
10.1038/s41580-019-0131-5
10.1126/science.aaq0180
10.1016/j.cell.2018.02.033
10.1038/nature13769
10.1073/pnas.1314307110
10.1186/s13046-019-1059-5
10.1016/j.addr.2020.10.014
10.1038/nrd.2016.246
10.1038/jid.1994.15
10.1016/j.addr.2015.01.007
10.1126/sciadv.abf4398
10.1186/s12943-021-01335-5
10.1126/science.aau6977
10.1038/mt.2016.10
10.3389/fimmu.2017.01182
10.1038/nbt.3802
10.1016/j.molcel.2021.11.019
10.1016/S0092-8674(04)00045-5
10.1038/cr.2016.22
10.3390/ijms22179168
10.1007/s10555-017-9717-6
10.1038/nrd1955
10.1016/j.addr.2019.08.004
10.1038/nrd.2017.239
10.1016/j.tips.2018.09.001
10.1038/ncb1596
10.1021/acs.nanolett.0c00596
10.1007/s40265-021-01480-7
10.1038/s41565-020-0669-6
10.1016/j.biomaterials.2015.02.099
10.1093/nar/27.6.1547
10.1158/1078-0432.CCR-20-0414
10.1038/s41591-018-0327-9
10.7554/eLife.32724
10.3389/fgene.2012.00154
10.1007/s40265-020-01410-z
10.1089/nat.2017.0665
10.1093/nar/29.6.1293
10.1038/35078107
10.1002/emmm.201202287
10.1016/j.cca.2005.11.023
10.1093/nar/gkw076
10.1016/j.jconrel.2015.01.017
10.1038/nature04791
10.1073/pnas.1305804110
10.1073/pnas.75.1.280
10.1038/mtm.2016.14
10.1038/mt.2012.202
10.1126/science.1690918
10.1016/j.tibtech.2015.08.001
10.1021/acs.nanolett.0c05039
10.1007/s11095-017-2134-2
10.1056/NEJMoa1716793
10.1093/nsr/nwaa033
10.1016/j.copbio.2021.09.016
10.1038/nrd4278
10.1517/14712598.2013.774366
10.1038/355850a0
10.4155/tde.13.47
10.1016/j.ymthe.2016.10.019
10.1126/scitranslmed.3006839
10.1056/NEJMoa1813279
10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H
10.1038/nm.1932
10.1126/science.1258096
10.1186/s12943-021-01339-1
10.1073/pnas.171251798
10.1016/j.aca.2013.12.023
10.1038/nnano.2012.73
10.1128/AAC.40.9.2004
10.1007/s40265-020-01463-0
10.1038/nature08956
10.1016/j.ymthe.2017.06.002
10.1038/s41380-018-0266-3
10.1021/acs.jmedchem.6b00551
10.1002/adma.201902798
10.3390/molecules26216530
10.1038/nature11993
10.1007/s40265-020-01267-2
10.1073/pnas.82.1.144
10.1038/nrg1500
10.1016/j.cmet.2018.03.004
10.1093/nar/gkl1071
10.1101/gad.862301
10.1016/j.biotechadv.2019.03.016
10.1016/j.addr.2020.06.026
10.1016/j.ymthe.2020.04.006
10.3390/ijms18081683
10.1007/s40265-021-01512-2
10.1038/s41573-021-00283-5
10.1038/35888
10.1038/nnano.2011.187
10.1038/nbt.3589
10.1038/nbt.2612
10.1093/nar/gku184
10.1021/mp500047b
10.2165/00003495-199957030-00010
10.1016/j.cbpa.2009.08.003
10.1038/nature07758
10.1016/S0140-6736(11)61028-3
10.1002/cncr.26730
10.1093/nar/gkx632
10.1002/cbdv.201100081
10.1093/nar/30.9.1911
10.1016/j.biomaterials.2017.11.034
10.1038/s41467-018-03927-0
10.2174/1389201019666180611093428
10.1021/nn300727j
10.1146/annurev-biophys-083012-130404
10.1093/nar/gkx1199
10.1371/journal.pcbi.1004656
10.1016/j.addr.2015.02.007
10.3390/ph4121591
10.1016/j.coph.2010.07.002
10.1126/science.1147535
10.1093/nar/gkv228
10.1016/j.msec.2016.07.066
10.1038/s41573-021-00219-z
10.1038/nbt.3290
10.1186/s12943-021-01311-z
10.1073/pnas.0607015103
10.1038/nrd.2016.117
10.1038/mt.2015.71
10.1038/nbt1216-1213
10.1038/d41573-020-00078-0
10.1002/adhm.201600418
10.1056/NEJMoa2035389
10.1038/s41573-021-00162-z
10.1038/nbt.3765
10.1038/nature11928
10.1038/nrd.2018.93
10.3390/molecules24234229
10.1038/s41573-019-0017-4
10.1056/NEJMoa1716153
10.1016/j.tips.2021.03.002
10.1038/nrd4359
10.1016/j.bbcan.2020.188491
10.1016/j.addr.2016.01.022
10.1126/science.aaf5573
10.1038/nrd.2016.199
10.1038/nn.4508
10.1002/wrna.121
10.4049/jimmunol.0902308
10.1007/s40259-018-0290-5
10.1038/s41586-020-2622-0
10.1039/D0CS01261K
10.1007/s13238-020-00700-2
10.1016/j.molcel.2020.04.030
10.1093/nar/gkx818
10.1021/mp900015y
10.1089/nat.2014.0506
10.1007/s40265-020-01269-0
10.1186/s12943-021-01348-0
10.1038/mt.2008.200
10.1038/nrg2006
10.1016/j.addr.2012.08.008
10.1038/mtna.2014.21
10.1016/j.cell.2022.03.044
10.1101/gr.231936.117
10.1007/s40265-020-01339-3
10.1016/j.molmed.2019.08.012
10.1038/nchembio860
10.1038/s41573-019-0042-3
10.1007/s11883-019-0809-3
10.1002/wrna.1627
10.1002/0471142700.nc0446s46
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41419-022-05075-2
DatabaseName SpringerOpen website
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
CrossRef


MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: ProQuest Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-4889
EndPage 15
ExternalDocumentID oai_doaj_org_article_5d38d50915d9431a8393e1cee30c8f55
PMC9308039
35871216
10_1038_s41419_022_05075_2
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 81903061,91740106; 81903061,91740106; 81903061,91740106; 81903061,91740106
  funderid: https://doi.org/10.13039/501100001809
– fundername: ;
  grantid: 81903061,91740106; 81903061,91740106; 81903061,91740106; 81903061,91740106
GroupedDBID ---
0R~
3V.
53G
5VS
70F
7X7
88A
88I
8FE
8FH
8FI
8FJ
AAJSJ
ABUWG
ACGFS
ACSMW
ADBBV
AENEX
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
E3Z
EBLON
EBS
EMOBN
FRP
FYUFA
GNUQQ
GROUPED_DOAJ
HCIFZ
HMCUK
HYE
HZ~
KQ8
LK8
M0L
M2P
M48
M7P
M~E
NAO
O5R
O5S
O9-
OK1
PIMPY
PQQKQ
PROAC
RNT
RPM
SNYQT
TR2
UKHRP
W2D
AASML
AAYXX
AFFHD
CITATION
PHGZM
PHGZT
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
COVID
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c606t-dddc1cc4d3c798e1bcd42afb547be5d050ad58544f8cd47ae7db2e7f4fc841e83
IEDL.DBID DOA
ISICitedReferencesCount 383
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000830022100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2041-4889
IngestDate Mon Nov 10 04:34:31 EST 2025
Tue Nov 04 01:56:22 EST 2025
Thu Sep 04 19:31:07 EDT 2025
Tue Oct 07 07:09:22 EDT 2025
Thu Apr 03 07:08:50 EDT 2025
Tue Nov 18 20:59:25 EST 2025
Sat Nov 29 05:57:27 EST 2025
Fri Feb 21 02:37:10 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c606t-dddc1cc4d3c798e1bcd42afb547be5d050ad58544f8cd47ae7db2e7f4fc841e83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-6697-3097
OpenAccessLink https://doaj.org/article/5d38d50915d9431a8393e1cee30c8f55
PMID 35871216
PQID 2693185691
PQPubID 2041963
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_5d38d50915d9431a8393e1cee30c8f55
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9308039
proquest_miscellaneous_2693771589
proquest_journals_2693185691
pubmed_primary_35871216
crossref_citationtrail_10_1038_s41419_022_05075_2
crossref_primary_10_1038_s41419_022_05075_2
springer_journals_10_1038_s41419_022_05075_2
PublicationCentury 2000
PublicationDate 2022-07-23
PublicationDateYYYYMMDD 2022-07-23
PublicationDate_xml – month: 07
  year: 2022
  text: 2022-07-23
  day: 23
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Cell death & disease
PublicationTitleAbbrev Cell Death Dis
PublicationTitleAlternate Cell Death Dis
PublicationYear 2022
Publisher Nature Publishing Group UK
Springer Nature B.V
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
– name: Nature Publishing Group
References Wolff, Malone, Williams, Chong, Acsadi, Jani (CR56) 1990; 247
Abudayyeh, Gootenberg, Konermann, Joung, Slaymaker, Cox (CR51) 2016; 353
Dowdy (CR59) 2017; 35
Drury, O’Connor, Pollard (CR138) 2017; 8
Chen, Wang, Zeng, Urayama, Yu (CR165) 2015; 43
Toden, Zumwalt, Goel (CR157) 2021; 1875
Desterro, Bak-Gordon, Carmo-Fonseca (CR15) 2020; 19
Elbashir, Lendeckel, Tuschl (CR30) 2001; 15
Wang, Wang, Zou, Duan, Li, Deng (CR9) 2019; 37
Nielsen (CR72) 2005; 288
Beck, Reidenbach, Salomon, Sahin, Türeci, Vormehr (CR58) 2021; 20
Sellner, Kocabey, Nekolla, Krombach, Liedl, Rehberg (CR115) 2015; 53
Scott (CR134) 2020; 80
Chaudhary, Weissman, Whitehead (CR57) 2021; 20
Medley, Panzade, Zinovyeva (CR35) 2021; 12
Vasudevan (CR37) 2012; 3
Wan, Seth (CR64) 2016; 59
Dhillon (CR123) 2020; 80
Maeder, Gersbach (CR145) 2016; 24
Kurreck, Wyszko, Gillen, Erdmann (CR69) 2002; 30
Melton (CR20) 1985; 82
Ward, Norrbom, Chun, Bennett, Rigo (CR19) 2014; 42
Pollard, Rejman, De Haes, Verrier, Van Gulck, Naessens (CR102) 2013; 21
Liu, Guo, Nan, Xu, Yang, Chen (CR155) 2022; 82
Baker, Lot, Kringel, Cheng-Flournoy, Villiet, Sasmor (CR21) 1999; 27
Cheng, Wei, Farbiak, Johnson, Dilliard, Siegwart (CR95) 2020; 15
Portnoy, Lin, Li, Burlingame, Hu, Li (CR44) 2016; 26
Kalluri, LeBleu (CR104) 2020; 367
Matzke, Birchler (CR33) 2005; 6
Maier, Levy (CR85) 2016; 5
Bramsen, Kjems (CR61) 2012; 3
Anderson, Fox, Brown-Driver, Martin, Azad (CR119) 1996; 40
Sun, Ji, Hall, Hu, Wang, Beisel (CR114) 2015; 54
Khvorova, Watts (CR60) 2017; 35
Winkler (CR70) 2013; 4
Dirin, Winkler (CR67) 2013; 13
He, Peng, Huang, Zhang, Zhou, Yang (CR160) 2020; 11
Liang, Sun, Nichols, Crooke (CR12) 2017; 25
Memczak, Jens, Elefsinioti, Torti, Krueger, Rybak (CR152) 2013; 495
Maeder, Stefanidakis, Wilson, Baral, Barrera, Bounoutas (CR144) 2019; 25
Hajj, Melamed, Chaudhary, Lamson, Ball, Yerneni (CR93) 2020; 20
Ryan, Taussig, Steinfeld, Phadnis, Lunstad, Singh (CR79) 2018; 46
Setten, Lightfoot, Habib, Rossi (CR141) 2018; 19
Ellington, Szostak (CR53) 1992; 355
Ni, Yao, Wang, Lu, Jiang, Lu (CR82) 2017; 18
Shirley (CR124) 2021; 81
Eckstein (CR65) 2014; 24
Heo (CR122) 2020; 80
Jensen, Day, Ko, Hurley, Luciano, Kouri (CR109) 2013; 5
Dhillon (CR169) 2020; 80
Chen, Zhang, Yin (CR77) 2021; 168
Baba, Itaka, Kondo, Yamasoba, Kataoka (CR103) 2015; 201
Garber (CR132) 2016; 34
Li, Rana (CR25) 2014; 13
Beane, Lee, Zheng, Mendel, Abate-Daga, Bharathan (CR143) 2015; 23
Mao, Sun, Kissel (CR99) 2010; 62
Doudna, Charpentier (CR47) 2014; 346
Elbashir, Harborth, Lendeckel, Yalcin, Weber, Tuschl (CR2) 2001; 411
Gilleron, Querbes, Zeigerer, Borodovsky, Marsico, Schubert (CR91) 2013; 31
Aartsma-Rus (CR121) 2017; 27
Titze-de-Almeida, David, Titze-de-Almeida (CR137) 2017; 34
Dixon, Stockwell (CR6) 2009; 13
Kim, Hu, Moufawad El Achkar, Black, Douville, Larson (CR125) 2019; 381
Liang, Shen, Sun, Migawa, Vickers, Crooke (CR23) 2016; 34
Bartel (CR34) 2004; 116
Kim, Koo, Jee, Cho, Lee, Lim (CR80) 2018; 28
Nair, Attarwala, Sehgal, Wang, Aluri, Zhang (CR133) 2017; 45
Heine, Juranek, Brossart (CR150) 2021; 20
Kim, Jeong, Hur, Cho, Park, Jung (CR94) 2021; 7
Corbett, Edwards, Leist, Abiona, Boyoglu-Barnum, Gillespie (CR149) 2020; 586
Wang, Zhang, Luo, Han, Wei, Wei (CR73) 2021; 20
Li, Mastaglia, Fletcher, Wilton (CR16) 2018; 39
Liang, Sun, Shen, Wang, Yao, Migawa (CR24) 2017; 45
Falese, Donlic, Hargrove (CR5) 2021; 50
Adams, Gonzalez-Duarte, O’Riordan, Yang, Ueda, Kristen (CR129) 2018; 379
Sahin, Karikó, Türeci (CR7) 2014; 13
Scott, Keam (CR135) 2021; 81
Linko, Ora, Kostiainen (CR111) 2015; 33
Kon, Elia, Peer (CR74) 2022; 73
Morrow, Murthy, Ensor, Gordon, Margolin, Elias (CR127) 2012; 118
Grimm, Streetz, Jopling, Storm, Pandey, Davis (CR163) 2006; 441
Wang, Zuroske, Watts (CR3) 2020; 19
Kapadia, Melamed, Day (CR110) 2018; 32
Strutt, Torrez, Kaya, Negrete, Doudna (CR49) 2018; 7
Corey (CR18) 2017; 20
Cheng, Lee (CR88) 2016; 99
Zamecnik, Stephenson (CR1) 1978; 75
Cox, Gootenberg, Abudayyeh, Franklin, Kellner, Joung (CR52) 2017; 358
Paunovska, Loughrey, Sago, Langer, Dahlman (CR167) 2019; 31
Blom, Raal, Santos, Marais (CR120) 2019; 21
Zorde Khvalevsky, Gabai, Rachmut, Horwitz, Brunschwig, Orbach (CR136) 2013; 110
Ozcan, Ozpolat, Coleman, Sood, Lopez-Berestein (CR87) 2015; 87
Hendel, Bak, Clark, Kennedy, Ryan, Roy (CR78) 2015; 33
Lee, Lytton-Jean, Chen, Love, Park, Karagiannis (CR112) 2012; 7
Chen, Mangala, Rodriguez-Aguayo, Kong, Lopez-Berestein, Sood (CR62) 2018; 37
Long, Maloney, Rogers, Lahiri (CR38) 2019; 24
Charoenphol, Bermudez (CR113) 2014; 11
Iversen (CR71) 2001; 3
Konermann, Lotfy, Brideau, Oki, Shokhirev, Hsu (CR50) 2018; 173
Lavenniah, Luu, Li, Lim, Jiang, Ackers-Johnson (CR154) 2020; 28
Shi, He, Cui, Wang, Deng, Li (CR84) 2014; 812
Baden, El Sahly, Essink, Kotloff, Frey, Novak (CR148) 2021; 384
Fire, Xu, Montgomery, Kostas, Driver, Mello (CR28) 1998; 391
Ma, Liu, Li, Wang, Li, Lu (CR39) 2010; 184
Choi, Hao, Narayan, Auyeung, Mirkin (CR108) 2013; 110
Harvie, Wong, Bally (CR89) 2000; 89
Kim, Kim, Yu, Lee, Park, Choi (CR36) 2020; 78
Patel, Ibrahim, Cheng (CR92) 2021; 42
Pickar-Oliver, Gersbach (CR46) 2019; 20
Zimmermann, Karsten, Chan, Chiesa, Boyce, Bettencourt (CR131) 2017; 25
Patel, Kim, Herrera, Mukherjee, Kabanov, Sahay (CR166) 2019; 144
Warner, Hajdin, Weeks (CR170) 2018; 17
Crooke, Witztum, Bennett, Baker (CR4) 2018; 27
Valadi, Ekström, Bossios, Sjöstrand, Lee, Lötvall (CR106) 2007; 9
Mohri, Nishikawa, Takahashi, Shiomi, Matsuoka, Ogawa (CR116) 2012; 6
Adachi, Nakamura (CR10) 2019; 24
Miao, Zhang, Huang (CR151) 2021; 20
CR83
Wilson, Doudna (CR32) 2013; 42
Cromwell, Sung, Park, Krysler, Jovel, Kim (CR81) 2018; 9
Höbel, Appeldoorn, Gaillard, Aigner (CR97) 2011; 4
Swayze, Siwkowski, Wancewicz, Migawa, Wyrzykiewicz, Hung (CR164) 2007; 35
Rupaimoole, Slack (CR40) 2017; 16
Kwon, Kim, Seo, Moon, Lee, Lee (CR76) 2018; 156
Khan (CR126) 2006; 367
Mitsuyasu, Merigan, Carr, Zack, Winters, Workman (CR128) 2009; 15
El Andaloussi, Lakhal, Mäger, Wood (CR105) 2013; 65
Huang, Tan, Reebye, Chee, Zacharoulis, Habib (CR142) 2021; 22
Davis, Zuckerman, Choi, Seligson, Tolcher, Alabi (CR100) 2010; 464
Lamb (CR147) 2021; 81
Zhou, Hu, Tang, Liu, Wang, Zhou (CR161) 2020; 7
Witzigmann, Kulkarni, Leung, Chen, Cullis, van der Meel (CR90) 2020; 159
Janowski, Younger, Hardy, Ram, Huffman, Corey (CR42) 2007; 3
Kim, Rossi (CR27) 2007; 8
Ho, Zhang, Xu (CR63) 2016; 5
Mokhtarzadeh, Vahidnezhad, Youssefian, Mosafer, Baradaran, Uitto (CR107) 2019; 25
Pandey, Sawant (CR98) 2016; 68
Zhou, Rossi (CR54) 2017; 16
Zhou, Rossi (CR55) 2014; 3
Davis (CR101) 2009; 6
Setten, Rossi, Han (CR68) 2019; 18
Kaufmann, Büning, Galy, Schambach, Grez (CR8) 2013; 5
Benson, Waddington-Cruz, Berk, Polydefkis, Dyck, Wang (CR130) 2018; 379
Kamola, Nakano, Takahashi, Wilson, Ui-Tei (CR162) 2015; 11
Caplen, Parrish, Imani, Fire, Morgan (CR29) 2001; 98
Perry, Balfour (CR118) 1999; 57
Mullard (CR168) 2017; 16
Matsui, Corey (CR158) 2017; 16
Castanotto, Rossi (CR31) 2009; 457
Li, Okino, Zhao, Pookot, Place, Urakami (CR41) 2006; 103
Nakamura, Takeda (CR17) 2011; 378
Sarker, Plummer, Meyer, Sodergren, Basu, Chee (CR140) 2020; 26
Pinheiro, Han, Shih, Yan (CR117) 2011; 6
Hansen, Jensen, Clausen, Bramsen, Finsen, Damgaard (CR153) 2013; 495
Yin, Li, Ma, Zhang, Yu, Zhao (CR96) 2021; 21
Wang, Miao, Satterlee, Huang (CR86) 2015; 87
Qu, Yi, Shen, Lin, Chen, Xu (CR156) 2022; 185
Tan, Sinigaglia, Gomez, Nicholls, Habib (CR45) 2021; 26
Vickers, Wyatt, Burckin, Bennett, Freier (CR22) 2001; 29
Karikó, Muramatsu, Welsh, Ludwig, Kato, Akira (CR75) 2008; 16
Ng, Shima, Calias, Cunningham, Guyer, Adamis (CR146) 2006; 5
Prakash (CR66) 2011; 8
Mulhbacher, St-Pierre, Lafontaine (CR13) 2010; 10
Sullivan (CR14) 1994; 103
Meng, Jiang, Chang, Wang, Liu, Xiong (CR43) 2016; 44
Winkle, El-Daly, Fabbri, Calin (CR159) 2021; 20
Choi, Giraldez, Schier (CR26) 2007; 318
Zhang, Liao, Tang (CR139) 2019; 38
Crooke, Baker, Crooke, Liang (CR11) 2021; 20
O’Connell, Oakes, Sternberg, East-Seletsky, Kaplan, Doudna (CR48) 2014; 516
Q Cheng (5075_CR95) 2020; 15
P Harvie (5075_CR89) 2000; 89
W Ho (5075_CR63) 2016; 5
A Fire (5075_CR28) 1998; 391
CX Liu (5075_CR155) 2022; 82
Z Li (5075_CR25) 2014; 13
X Meng (5075_CR43) 2016; 44
Q Chen (5075_CR77) 2021; 168
J Winkler (5075_CR70) 2013; 4
S Vasudevan (5075_CR37) 2012; 3
F Ma (5075_CR39) 2010; 184
R Titze-de-Almeida (5075_CR137) 2017; 34
KS Corbett (5075_CR149) 2020; 586
L Zhang (5075_CR139) 2019; 38
J Desterro (5075_CR15) 2020; 19
J Kim (5075_CR125) 2019; 381
H Lee (5075_CR112) 2012; 7
SM Elbashir (5075_CR2) 2001; 411
AU Khan (5075_CR126) 2006; 367
B He (5075_CR160) 2020; 11
H Shi (5075_CR84) 2014; 812
F Wang (5075_CR3) 2020; 19
JC Medley (5075_CR35) 2021; 12
X Chen (5075_CR62) 2018; 37
PC Zamecnik (5075_CR1) 1978; 75
E Zorde Khvalevsky (5075_CR136) 2013; 110
Y Yin (5075_CR96) 2021; 21
S El Andaloussi (5075_CR105) 2013; 65
K Karikó (5075_CR75) 2008; 16
EW Ng (5075_CR146) 2006; 5
A Mokhtarzadeh (5075_CR107) 2019; 25
L Qu (5075_CR156) 2022; 185
D Grimm (5075_CR163) 2006; 441
RL Setten (5075_CR68) 2019; 18
DBT Cox (5075_CR52) 2017; 358
XH Liang (5075_CR23) 2016; 34
H Kwon (5075_CR76) 2018; 156
D Witzigmann (5075_CR90) 2020; 159
A Khvorova (5075_CR60) 2017; 35
T Adachi (5075_CR10) 2019; 24
ML Maeder (5075_CR145) 2016; 24
ST Crooke (5075_CR4) 2018; 27
DR Corey (5075_CR18) 2017; 20
N Chaudhary (5075_CR57) 2021; 20
MD Benson (5075_CR130) 2018; 379
DP Bartel (5075_CR34) 2004; 116
C Pollard (5075_CR102) 2013; 21
ML Maeder (5075_CR144) 2019; 25
SM Elbashir (5075_CR30) 2001; 15
G Ozcan (5075_CR87) 2015; 87
CM Perry (5075_CR118) 1999; 57
TS Zimmermann (5075_CR131) 2017; 25
XH Liang (5075_CR24) 2017; 45
AD Ellington (5075_CR53) 1992; 355
A Hendel (5075_CR78) 2015; 33
BA Janowski (5075_CR42) 2007; 3
WB Wan (5075_CR64) 2016; 59
ME Davis (5075_CR100) 2010; 464
CH Choi (5075_CR108) 2013; 110
A Heine (5075_CR150) 2021; 20
K Garber (5075_CR132) 2016; 34
M Kim (5075_CR94) 2021; 7
RT Mitsuyasu (5075_CR128) 2009; 15
JD Beane (5075_CR143) 2015; 23
F Eckstein (5075_CR65) 2014; 24
J Gilleron (5075_CR91) 2013; 31
KB Kaufmann (5075_CR8) 2013; 5
Y Wang (5075_CR73) 2021; 20
S Mao (5075_CR99) 2010; 62
CR Cromwell (5075_CR81) 2018; 9
BF Baker (5075_CR21) 1999; 27
AP Pandey (5075_CR98) 2016; 68
D Adams (5075_CR129) 2018; 379
H Kim (5075_CR36) 2020; 78
E Kon (5075_CR74) 2022; 73
KP Anderson (5075_CR119) 1996; 40
RE Drury (5075_CR138) 2017; 8
S Toden (5075_CR157) 2021; 1875
S Konermann (5075_CR50) 2018; 173
ME Davis (5075_CR101) 2009; 6
RC Wilson (5075_CR32) 2013; 42
MA Matzke (5075_CR33) 2005; 6
S Sellner (5075_CR115) 2015; 53
QX Chen (5075_CR165) 2015; 43
U Sahin (5075_CR7) 2014; 13
S Patel (5075_CR166) 2019; 144
M Baba (5075_CR103) 2015; 201
DH Kim (5075_CR27) 2007; 8
MR O’Connell (5075_CR48) 2014; 516
J Zhou (5075_CR55) 2014; 3
JD Beck (5075_CR58) 2021; 20
S Memczak (5075_CR152) 2013; 495
M Shirley (5075_CR124) 2021; 81
YA Heo (5075_CR122) 2020; 80
Y Wang (5075_CR86) 2015; 87
WY Choi (5075_CR26) 2007; 318
TP Prakash (5075_CR66) 2011; 8
J Mulhbacher (5075_CR13) 2010; 10
L Miao (5075_CR151) 2021; 20
TB Hansen (5075_CR153) 2013; 495
A Nakamura (5075_CR17) 2011; 378
CH Kapadia (5075_CR110) 2018; 32
X Cheng (5075_CR88) 2016; 99
P Patel (5075_CR92) 2021; 42
KW Huang (5075_CR142) 2021; 22
OO Abudayyeh (5075_CR51) 2016; 353
V Linko (5075_CR111) 2015; 33
V Portnoy (5075_CR44) 2016; 26
JA Wolff (5075_CR56) 1990; 247
JK Nair (5075_CR133) 2017; 45
CP Tan (5075_CR45) 2021; 26
M Dirin (5075_CR67) 2013; 13
S Kim (5075_CR80) 2018; 28
PK Morrow (5075_CR127) 2012; 118
LJ Scott (5075_CR134) 2020; 80
SC Strutt (5075_CR49) 2018; 7
LR Baden (5075_CR148) 2021; 384
SJ Dixon (5075_CR6) 2009; 13
C Zhou (5075_CR161) 2020; 7
J Kurreck (5075_CR69) 2002; 30
EE Swayze (5075_CR164) 2007; 35
K Paunovska (5075_CR167) 2019; 31
NJ Caplen (5075_CR29) 2001; 98
S Höbel (5075_CR97) 2011; 4
D Sarker (5075_CR140) 2020; 26
A Pickar-Oliver (5075_CR46) 2019; 20
RL Setten (5075_CR141) 2018; 19
DA Melton (5075_CR20) 1985; 82
P Charoenphol (5075_CR113) 2014; 11
H Valadi (5075_CR106) 2007; 9
PJ Kamola (5075_CR162) 2015; 11
D Castanotto (5075_CR31) 2009; 457
JA Doudna (5075_CR47) 2014; 346
KA Hajj (5075_CR93) 2020; 20
R Rupaimoole (5075_CR40) 2017; 16
S Ni (5075_CR82) 2017; 18
SF Dowdy (5075_CR59) 2017; 35
JB Bramsen (5075_CR61) 2012; 3
PE Nielsen (5075_CR72) 2005; 288
KD Warner (5075_CR170) 2018; 17
S Dhillon (5075_CR123) 2020; 80
LC Li (5075_CR41) 2006; 103
ST Crooke (5075_CR11) 2021; 20
SA Jensen (5075_CR109) 2013; 5
KE Maier (5075_CR85) 2016; 5
AV Pinheiro (5075_CR117) 2011; 6
A Mullard (5075_CR168) 2017; 16
J Falese (5075_CR5) 2021; 50
TA Vickers (5075_CR22) 2001; 29
J Zhou (5075_CR54) 2017; 16
5075_CR83
R Kalluri (5075_CR104) 2020; 367
AJ Ward (5075_CR19) 2014; 42
DE Ryan (5075_CR79) 2018; 46
A Aartsma-Rus (5075_CR121) 2017; 27
JM Long (5075_CR38) 2019; 24
K Mohri (5075_CR116) 2012; 6
PL Iversen (5075_CR71) 2001; 3
S Dhillon (5075_CR169) 2020; 80
DJ Blom (5075_CR120) 2019; 21
A Lavenniah (5075_CR154) 2020; 28
M Matsui (5075_CR158) 2017; 16
D Li (5075_CR16) 2018; 39
SM Sullivan (5075_CR14) 1994; 103
YN Lamb (5075_CR147) 2021; 81
W Sun (5075_CR114) 2015; 54
LJ Scott (5075_CR135) 2021; 81
M Winkle (5075_CR159) 2021; 20
F Wang (5075_CR9) 2019; 37
XH Liang (5075_CR12) 2017; 25
References_xml – volume: 54
  start-page: 12029
  year: 2015
  end-page: 33
  ident: CR114
  article-title: Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201506030
– volume: 62
  start-page: 12
  year: 2010
  end-page: 27
  ident: CR99
  article-title: Chitosan-based formulations for delivery of DNA and siRNA
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2009.08.004
– volume: 20
  start-page: 490
  year: 2019
  end-page: 507
  ident: CR46
  article-title: The next generation of CRISPR-Cas technologies and applications
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-019-0131-5
– volume: 358
  start-page: 1019
  year: 2017
  end-page: 27
  ident: CR52
  article-title: RNA editing with CRISPR-Cas13
  publication-title: Science.
  doi: 10.1126/science.aaq0180
– volume: 173
  start-page: 665
  year: 2018
  end-page: 76.e14
  ident: CR50
  article-title: Transcriptome engineering with RNA-targeting type VI-D CRISPR effectors
  publication-title: Cell
  doi: 10.1016/j.cell.2018.02.033
– volume: 516
  start-page: 263
  year: 2014
  end-page: 6
  ident: CR48
  article-title: Programmable RNA recognition and cleavage by CRISPR/Cas9
  publication-title: Nature.
  doi: 10.1038/nature13769
– volume: 110
  start-page: 20723
  year: 2013
  end-page: 8
  ident: CR136
  article-title: Mutant KRAS is a druggable target for pancreatic cancer
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1314307110
– volume: 38
  start-page: 53
  year: 2019
  ident: CR139
  article-title: MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-019-1059-5
– volume: 168
  start-page: 246
  year: 2021
  end-page: 58
  ident: CR77
  article-title: Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.10.014
– volume: 16
  start-page: 203
  year: 2017
  end-page: 22
  ident: CR40
  article-title: MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.246
– volume: 103
  start-page: 85s
  issue: 5 Suppl
  year: 1994
  end-page: 9s
  ident: CR14
  article-title: Development of ribozymes for gene therapy
  publication-title: J Investig Dermatol
  doi: 10.1038/jid.1994.15
– volume: 87
  start-page: 108
  year: 2015
  end-page: 19
  ident: CR87
  article-title: Preclinical and clinical development of siRNA-based therapeutics
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2015.01.007
– volume: 7
  start-page: eabf4398
  year: 2021
  ident: CR94
  article-title: Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abf4398
– volume: 20
  year: 2021
  ident: CR151
  article-title: mRNA vaccine for cancer immunotherapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01335-5
– volume: 367
  start-page: eaau6977
  year: 2020
  ident: CR104
  article-title: The biology, function, and biomedical applications of exosomes
  publication-title: Science
  doi: 10.1126/science.aau6977
– volume: 24
  start-page: 430
  year: 2016
  end-page: 46
  ident: CR145
  article-title: Genome-editing technologies for gene and cell therapy
  publication-title: Mol Ther
  doi: 10.1038/mt.2016.10
– volume: 8
  start-page: 1182
  year: 2017
  ident: CR138
  article-title: The clinical application of MicroRNAs in infectious disease
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.01182
– volume: 35
  start-page: 222
  year: 2017
  end-page: 9
  ident: CR59
  article-title: Overcoming cellular barriers for RNA therapeutics
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3802
– volume: 12
  start-page: e1627
  year: 2021
  ident: CR35
  article-title: microRNA strand selection: unwinding the rules
  publication-title: Wiley Interdiscip Rev Rna.
– volume: 82
  start-page: 420
  year: 2022
  end-page: 34.e6
  ident: CR155
  article-title: RNA circles with minimized immunogenicity as potent PKR inhibitors
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2021.11.019
– volume: 116
  start-page: 281
  year: 2004
  end-page: 97
  ident: CR34
  article-title: MicroRNAs: genomics, biogenesis, mechanism, and function
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
– volume: 26
  start-page: 320
  year: 2016
  end-page: 35
  ident: CR44
  article-title: saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription
  publication-title: Cell Res
  doi: 10.1038/cr.2016.22
– volume: 22
  start-page: 9168
  year: 2021
  ident: CR142
  article-title: MTL-CEBPA combined with immunotherapy or RFA enhances immunological anti-tumor response in preclinical models
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22179168
– volume: 37
  start-page: 107
  year: 2018
  end-page: 24
  ident: CR62
  article-title: RNA interference-based therapy and its delivery systems
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-017-9717-6
– volume: 5
  start-page: 123
  year: 2006
  end-page: 32
  ident: CR146
  article-title: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1955
– volume: 144
  start-page: 90
  year: 2019
  end-page: 111
  ident: CR166
  article-title: Brief update on endocytosis of nanomedicines
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2019.08.004
– volume: 16
  start-page: 813
  year: 2017
  end-page: 5
  ident: CR168
  article-title: Small molecules against RNA targets attract big backers
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2017.239
– volume: 39
  start-page: 982
  year: 2018
  end-page: 94
  ident: CR16
  article-title: Precision medicine through antisense oligonucleotide-mediated Exon skipping
  publication-title: Trends Pharm Sci
  doi: 10.1016/j.tips.2018.09.001
– volume: 9
  start-page: 654
  year: 2007
  end-page: 9
  ident: CR106
  article-title: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1596
– volume: 20
  start-page: 5167
  year: 2020
  end-page: 75
  ident: CR93
  article-title: A potent branched-tail lipid nanoparticle enables multiplexed mRNA delivery and gene editing in vivo
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.0c00596
– volume: 81
  start-page: 495
  year: 2021
  end-page: 501
  ident: CR147
  article-title: BNT162b2 mRNA COVID-19 vaccine: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-021-01480-7
– volume: 15
  start-page: 313
  year: 2020
  end-page: 20
  ident: CR95
  article-title: Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-020-0669-6
– volume: 53
  start-page: 453
  year: 2015
  end-page: 63
  ident: CR115
  article-title: DNA nanotubes as intracellular delivery vehicles in vivo
  publication-title: Biomaterials.
  doi: 10.1016/j.biomaterials.2015.02.099
– volume: 27
  start-page: 1547
  year: 1999
  end-page: 51
  ident: CR21
  article-title: Oligonucleotide-europium complex conjugate designed to cleave the 5’ cap structure of the ICAM-1 transcript potentiates antisense activity in cells
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/27.6.1547
– volume: 26
  start-page: 3936
  year: 2020
  end-page: 46
  ident: CR140
  article-title: MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-0414
– volume: 25
  start-page: 229
  year: 2019
  end-page: 33
  ident: CR144
  article-title: Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0327-9
– volume: 7
  start-page: e32724
  year: 2018
  ident: CR49
  article-title: RNA-dependent RNA targeting by CRISPR-Cas9
  publication-title: Elife
  doi: 10.7554/eLife.32724
– volume: 3
  start-page: 154
  year: 2012
  ident: CR61
  article-title: Development of therapeutic-grade small interfering RNAs by chemical engineering
  publication-title: Front Genet
  doi: 10.3389/fgene.2012.00154
– volume: 80
  start-page: 1853
  year: 2020
  end-page: 8
  ident: CR169
  article-title: Risdiplam: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-020-01410-z
– volume: 27
  start-page: 67
  year: 2017
  end-page: 9
  ident: CR121
  article-title: FDA approval of nusinersen for spinal muscular atrophy makes 2016 the year of splice modulating oligonucleotides
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2017.0665
– volume: 29
  start-page: 1293
  year: 2001
  end-page: 9
  ident: CR22
  article-title: Fully modified 2’ MOE oligonucleotides redirect polyadenylation
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/29.6.1293
– volume: 411
  start-page: 494
  year: 2001
  end-page: 8
  ident: CR2
  article-title: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
  publication-title: Nature
  doi: 10.1038/35078107
– volume: 5
  start-page: 1642
  year: 2013
  end-page: 61
  ident: CR8
  article-title: Gene therapy on the move
  publication-title: EMBO Mol Med
  doi: 10.1002/emmm.201202287
– volume: 288
  start-page: 343
  year: 2005
  end-page: 58
  ident: CR72
  article-title: Gene targeting using peptide nucleic acid
  publication-title: Methods Mol Biol
– volume: 367
  start-page: 20
  year: 2006
  end-page: 7
  ident: CR126
  article-title: Ribozyme: a clinical tool
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2005.11.023
– volume: 44
  start-page: 2274
  year: 2016
  end-page: 82
  ident: CR43
  article-title: Small activating RNA binds to the genomic target site in a seed-region-dependent manner
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw076
– volume: 201
  start-page: 41
  year: 2015
  end-page: 8
  ident: CR103
  article-title: Treatment of neurological disorders by introducing mRNA in vivo using polyplex nanomicelles
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2015.01.017
– volume: 441
  start-page: 537
  year: 2006
  end-page: 41
  ident: CR163
  article-title: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
  publication-title: Nature.
  doi: 10.1038/nature04791
– volume: 110
  start-page: 7625
  year: 2013
  end-page: 30
  ident: CR108
  article-title: Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1305804110
– volume: 75
  start-page: 280
  year: 1978
  end-page: 4
  ident: CR1
  article-title: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.75.1.280
– volume: 5
  start-page: 16014
  year: 2016
  ident: CR85
  article-title: From selection hits to clinical leads: progress in aptamer discovery
  publication-title: Mol Ther Methods Clin Dev
  doi: 10.1038/mtm.2016.14
– volume: 21
  start-page: 251
  year: 2013
  end-page: 9
  ident: CR102
  article-title: Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines
  publication-title: Mol Ther
  doi: 10.1038/mt.2012.202
– volume: 247
  start-page: 1465
  year: 1990
  end-page: 8
  ident: CR56
  article-title: Direct gene transfer into mouse muscle in vivo
  publication-title: Science.
  doi: 10.1126/science.1690918
– volume: 33
  start-page: 586
  year: 2015
  end-page: 94
  ident: CR111
  article-title: DNA nanostructures as smart drug-delivery vehicles and molecular devices
  publication-title: Trends Biotechnol
  doi: 10.1016/j.tibtech.2015.08.001
– volume: 21
  start-page: 2224
  year: 2021
  end-page: 31
  ident: CR96
  article-title: In situ transforming RNA nanovaccines from polyethylenimine functionalized graphene oxide hydrogel for durable cancer immunotherapy
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.0c05039
– volume: 34
  start-page: 1339
  year: 2017
  end-page: 63
  ident: CR137
  article-title: The race of 10 synthetic RNAi-based drugs to the pharmaceutical market
  publication-title: Pharm Res
  doi: 10.1007/s11095-017-2134-2
– volume: 379
  start-page: 22
  year: 2018
  end-page: 31
  ident: CR130
  article-title: Inotersen treatment for patients with hereditary transthyretin amyloidosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1716793
– volume: 7
  start-page: 835
  year: 2020
  end-page: 7
  ident: CR161
  article-title: CasRx-mediated RNA targeting prevents choroidal neovascularization in a mouse model of age-related macular degeneration
  publication-title: Natl Sci Rev
  doi: 10.1093/nsr/nwaa033
– volume: 73
  start-page: 329
  year: 2022
  end-page: 36
  ident: CR74
  article-title: Principles for designing an optimal mRNA lipid nanoparticle vaccine
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2021.09.016
– volume: 13
  start-page: 759
  year: 2014
  end-page: 80
  ident: CR7
  article-title: mRNA-based therapeutics−developing a new class of drugs
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4278
– volume: 13
  start-page: 875
  year: 2013
  end-page: 88
  ident: CR67
  article-title: Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.2013.774366
– volume: 355
  start-page: 850
  year: 1992
  end-page: 2
  ident: CR53
  article-title: Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures
  publication-title: Nature.
  doi: 10.1038/355850a0
– volume: 4
  start-page: 791
  year: 2013
  end-page: 809
  ident: CR70
  article-title: Oligonucleotide conjugates for therapeutic applications
  publication-title: Ther Deliv
  doi: 10.4155/tde.13.47
– volume: 25
  start-page: 71
  year: 2017
  end-page: 8
  ident: CR131
  article-title: Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2016.10.019
– volume: 5
  start-page: 209ra152
  year: 2013
  ident: CR109
  article-title: Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3006839
– volume: 381
  start-page: 1644
  year: 2019
  end-page: 52
  ident: CR125
  article-title: Patient-customized oligonucleotide therapy for a rare genetic disease
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1813279
– volume: 89
  start-page: 652
  year: 2000
  end-page: 63
  ident: CR89
  article-title: Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles
  publication-title: J Pharm Sci
  doi: 10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H
– volume: 15
  start-page: 285
  year: 2009
  end-page: 92
  ident: CR128
  article-title: Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells
  publication-title: Nat Med
  doi: 10.1038/nm.1932
– volume: 346
  start-page: 1258096
  year: 2014
  ident: CR47
  article-title: Genome editing. The new frontier of genome engineering with CRISPR-Cas9
  publication-title: Science.
  doi: 10.1126/science.1258096
– volume: 3
  start-page: 235
  year: 2001
  end-page: 8
  ident: CR71
  article-title: Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation
  publication-title: Curr Opin Mol Ther
– volume: 20
  year: 2021
  ident: CR150
  article-title: Clinical and immunological effects of mRNA vaccines in malignant diseases
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01339-1
– volume: 98
  start-page: 9742
  year: 2001
  end-page: 7
  ident: CR29
  article-title: Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.171251798
– volume: 812
  start-page: 138
  year: 2014
  end-page: 44
  ident: CR84
  article-title: Locked nucleic acid/DNA chimeric aptamer probe for tumor diagnosis with improved serum stability and extended imaging window in vivo
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2013.12.023
– volume: 7
  start-page: 389
  year: 2012
  end-page: 93
  ident: CR112
  article-title: Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2012.73
– volume: 40
  start-page: 2004
  year: 1996
  end-page: 11
  ident: CR119
  article-title: Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.40.9.2004
– volume: 81
  start-page: 277
  year: 2021
  end-page: 82
  ident: CR135
  article-title: Lumasiran: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-020-01463-0
– volume: 464
  start-page: 1067
  year: 2010
  end-page: 70
  ident: CR100
  article-title: Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
  publication-title: Nature.
  doi: 10.1038/nature08956
– volume: 25
  start-page: 2075
  year: 2017
  end-page: 92
  ident: CR12
  article-title: RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2017.06.002
– volume: 24
  start-page: 345
  year: 2019
  end-page: 63
  ident: CR38
  article-title: Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5’-untranslated region: Implications in Alzheimer’s disease
  publication-title: Mol Psychiatry
  doi: 10.1038/s41380-018-0266-3
– ident: CR83
– volume: 59
  start-page: 9645
  year: 2016
  end-page: 67
  ident: CR64
  article-title: The medicinal chemistry of therapeutic oligonucleotides
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.6b00551
– volume: 31
  start-page: e1902798
  year: 2019
  ident: CR167
  article-title: Using large datasets to understand nanotechnology
  publication-title: Adv Mater
  doi: 10.1002/adma.201902798
– volume: 26
  start-page: 6530
  year: 2021
  ident: CR45
  article-title: RNA activation-A novel approach to therapeutically upregulate gene transcription
  publication-title: Molecules
  doi: 10.3390/molecules26216530
– volume: 495
  start-page: 384
  year: 2013
  end-page: 8
  ident: CR153
  article-title: Natural RNA circles function as efficient microRNA sponges
  publication-title: Nature.
  doi: 10.1038/nature11993
– volume: 80
  start-page: 329
  year: 2020
  end-page: 33
  ident: CR122
  article-title: Golodirsen: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-020-01267-2
– volume: 82
  start-page: 144
  year: 1985
  end-page: 8
  ident: CR20
  article-title: Injected anti-sense RNAs specifically block messenger RNA translation in vivo
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.82.1.144
– volume: 6
  start-page: 24
  year: 2005
  end-page: 35
  ident: CR33
  article-title: RNAi-mediated pathways in the nucleus
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg1500
– volume: 27
  start-page: 714
  year: 2018
  end-page: 39
  ident: CR4
  article-title: RNA-targeted therapeutics
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.03.004
– volume: 35
  start-page: 687
  year: 2007
  end-page: 700
  ident: CR164
  article-title: Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkl1071
– volume: 15
  start-page: 188
  year: 2001
  end-page: 200
  ident: CR30
  article-title: RNA interference is mediated by 21- and 22-nucleotide RNAs
  publication-title: Genes Dev
  doi: 10.1101/gad.862301
– volume: 37
  start-page: 708
  year: 2019
  end-page: 29
  ident: CR9
  article-title: Advances in CRISPR-Cas systems for RNA targeting, tracking and editing
  publication-title: Biotechnol Adv
  doi: 10.1016/j.biotechadv.2019.03.016
– volume: 159
  start-page: 344
  year: 2020
  end-page: 63
  ident: CR90
  article-title: Lipid nanoparticle technology for therapeutic gene regulation in the liver
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.06.026
– volume: 28
  start-page: 1506
  year: 2020
  end-page: 17
  ident: CR154
  article-title: Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.04.006
– volume: 18
  start-page: 1683
  year: 2017
  ident: CR82
  article-title: Chemical modifications of nucleic acid aptamers for therapeutic purposes
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms18081683
– volume: 81
  start-page: 875
  year: 2021
  end-page: 9
  ident: CR124
  article-title: Casimersen: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-021-01512-2
– volume: 20
  start-page: 817
  year: 2021
  end-page: 38
  ident: CR57
  article-title: mRNA vaccines for infectious diseases: principles, delivery and clinical translation
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00283-5
– volume: 391
  start-page: 806
  year: 1998
  end-page: 11
  ident: CR28
  article-title: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
  publication-title: Nature.
  doi: 10.1038/35888
– volume: 6
  start-page: 763
  year: 2011
  end-page: 72
  ident: CR117
  article-title: Challenges and opportunities for structural DNA nanotechnology
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2011.187
– volume: 34
  start-page: 875
  year: 2016
  end-page: 80
  ident: CR23
  article-title: Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3589
– volume: 31
  start-page: 638
  year: 2013
  end-page: 46
  ident: CR91
  article-title: Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2612
– volume: 42
  start-page: 5871
  year: 2014
  end-page: 9
  ident: CR19
  article-title: Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku184
– volume: 11
  start-page: 1721
  year: 2014
  end-page: 5
  ident: CR113
  article-title: Aptamer-targeted DNA nanostructures for therapeutic delivery
  publication-title: Mol Pharm
  doi: 10.1021/mp500047b
– volume: 57
  start-page: 375
  year: 1999
  end-page: 80
  ident: CR118
  article-title: Fomivirsen
  publication-title: Drugs
  doi: 10.2165/00003495-199957030-00010
– volume: 13
  start-page: 549
  year: 2009
  end-page: 55
  ident: CR6
  article-title: Identifying druggable disease-modifying gene products
  publication-title: Curr Opin Chem Biol
  doi: 10.1016/j.cbpa.2009.08.003
– volume: 457
  start-page: 426
  year: 2009
  end-page: 33
  ident: CR31
  article-title: The promises and pitfalls of RNA-interference-based therapeutics
  publication-title: Nature.
  doi: 10.1038/nature07758
– volume: 378
  start-page: 546
  year: 2011
  end-page: 7
  ident: CR17
  article-title: Exon-skipping therapy for Duchenne muscular dystrophy
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(11)61028-3
– volume: 118
  start-page: 4098
  year: 2012
  end-page: 104
  ident: CR127
  article-title: An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer
  publication-title: Cancer.
  doi: 10.1002/cncr.26730
– volume: 45
  start-page: 9528
  year: 2017
  end-page: 46
  ident: CR24
  article-title: Antisense oligonucleotides targeting translation inhibitory elements in 5’ UTRs can selectively increase protein levels
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx632
– volume: 8
  start-page: 1616
  year: 2011
  end-page: 41
  ident: CR66
  article-title: An overview of sugar-modified oligonucleotides for antisense therapeutics
  publication-title: Chem Biodivers
  doi: 10.1002/cbdv.201100081
– volume: 30
  start-page: 1911
  year: 2002
  end-page: 8
  ident: CR69
  article-title: Design of antisense oligonucleotides stabilized by locked nucleic acids
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/30.9.1911
– volume: 156
  start-page: 172
  year: 2018
  end-page: 93
  ident: CR76
  article-title: Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine
  publication-title: Biomaterials.
  doi: 10.1016/j.biomaterials.2017.11.034
– volume: 9
  year: 2018
  ident: CR81
  article-title: Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-03927-0
– volume: 19
  start-page: 611
  year: 2018
  end-page: 21
  ident: CR141
  article-title: Development of MTL-CEBPA: small activating RNA drug for hepatocellular carcinoma
  publication-title: Curr Pharm Biotechnol
  doi: 10.2174/1389201019666180611093428
– volume: 6
  start-page: 5931
  year: 2012
  end-page: 40
  ident: CR116
  article-title: Design and development of nanosized DNA assemblies in polypod-like structures as efficient vehicles for immunostimulatory CpG motifs to immune cells
  publication-title: ACS Nano
  doi: 10.1021/nn300727j
– volume: 42
  start-page: 217
  year: 2013
  end-page: 39
  ident: CR32
  article-title: Molecular mechanisms of RNA interference
  publication-title: Annu Rev Biophys
  doi: 10.1146/annurev-biophys-083012-130404
– volume: 46
  start-page: 792
  year: 2018
  end-page: 803
  ident: CR79
  article-title: Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1199
– volume: 11
  start-page: e1004656
  year: 2015
  ident: CR162
  article-title: The siRNA non-seed region and its target sequences are auxiliary determinants of off-target effects
  publication-title: PLoS Comput Biol
  doi: 10.1371/journal.pcbi.1004656
– volume: 87
  start-page: 68
  year: 2015
  end-page: 80
  ident: CR86
  article-title: Delivery of oligonucleotides with lipid nanoparticles
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2015.02.007
– volume: 4
  start-page: 1591
  year: 2011
  end-page: 606
  ident: CR97
  article-title: Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma
  publication-title: Pharmaceuticals
  doi: 10.3390/ph4121591
– volume: 10
  start-page: 551
  year: 2010
  end-page: 6
  ident: CR13
  article-title: Therapeutic applications of ribozymes and riboswitches
  publication-title: Curr Opin Pharm
  doi: 10.1016/j.coph.2010.07.002
– volume: 318
  start-page: 271
  year: 2007
  end-page: 4
  ident: CR26
  article-title: Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430
  publication-title: Science.
  doi: 10.1126/science.1147535
– volume: 43
  start-page: 3857
  year: 2015
  end-page: 69
  ident: CR165
  article-title: A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkv228
– volume: 68
  start-page: 904
  year: 2016
  end-page: 18
  ident: CR98
  article-title: Polyethylenimine: a versatile, multifunctional non-viral vector for nucleic acid delivery
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2016.07.066
– volume: 20
  start-page: 629
  year: 2021
  end-page: 51
  ident: CR159
  article-title: Noncoding RNA therapeutics—challenges and potential solutions
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00219-z
– volume: 33
  start-page: 985
  year: 2015
  end-page: 9
  ident: CR78
  article-title: Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3290
– volume: 20
  year: 2021
  ident: CR73
  article-title: mRNA vaccine: a potential therapeutic strategy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01311-z
– volume: 103
  start-page: 17337
  year: 2006
  end-page: 42
  ident: CR41
  article-title: Small dsRNAs induce transcriptional activation in human cells
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0607015103
– volume: 16
  start-page: 167
  year: 2017
  end-page: 79
  ident: CR158
  article-title: Non-coding RNAs as drug targets
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.117
– volume: 23
  start-page: 1380
  year: 2015
  end-page: 90
  ident: CR143
  article-title: Clinical Scale Zinc Finger nuclease-mediated gene editing of PD-1 in tumor infiltrating lymphocytes for the treatment of metastatic melanoma
  publication-title: Mol Ther
  doi: 10.1038/mt.2015.71
– volume: 34
  start-page: 1213
  year: 2016
  end-page: 4
  ident: CR132
  article-title: Alnylam terminates revusiran program, stock plunges
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1216-1213
– volume: 19
  start-page: 441
  year: 2020
  end-page: 2
  ident: CR3
  article-title: RNA therapeutics on the rise
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/d41573-020-00078-0
– volume: 5
  start-page: 2715
  year: 2016
  end-page: 31
  ident: CR63
  article-title: Biomaterials in siRNA delivery: a comprehensive review
  publication-title: Adv Health Mater
  doi: 10.1002/adhm.201600418
– volume: 384
  start-page: 403
  year: 2021
  end-page: 16
  ident: CR148
  article-title: Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035389
– volume: 20
  start-page: 427
  year: 2021
  end-page: 53
  ident: CR11
  article-title: Antisense technology: an overview and prospectus
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00162-z
– volume: 35
  start-page: 238
  year: 2017
  end-page: 48
  ident: CR60
  article-title: The chemical evolution of oligonucleotide therapies of clinical utility
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3765
– volume: 495
  start-page: 333
  year: 2013
  end-page: 8
  ident: CR152
  article-title: Circular RNAs are a large class of animal RNAs with regulatory potency
  publication-title: Nature.
  doi: 10.1038/nature11928
– volume: 17
  start-page: 547
  year: 2018
  end-page: 58
  ident: CR170
  article-title: Principles for targeting RNA with drug-like small molecules
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2018.93
– volume: 24
  start-page: 4229
  year: 2019
  ident: CR10
  article-title: Aptamers: a review of their chemical properties and modifications for therapeutic application
  publication-title: Molecules.
  doi: 10.3390/molecules24234229
– volume: 18
  start-page: 421
  year: 2019
  end-page: 46
  ident: CR68
  article-title: The current state and future directions of RNAi-based therapeutics
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0017-4
– volume: 379
  start-page: 11
  year: 2018
  end-page: 21
  ident: CR129
  article-title: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1716153
– volume: 42
  start-page: 448
  year: 2021
  end-page: 60
  ident: CR92
  article-title: The importance of apparent pKa in the development of nanoparticles encapsulating siRNA and mRNA
  publication-title: Trends Pharm Sci
  doi: 10.1016/j.tips.2021.03.002
– volume: 13
  start-page: 622
  year: 2014
  end-page: 38
  ident: CR25
  article-title: Therapeutic targeting of microRNAs: current status and future challenges
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4359
– volume: 1875
  start-page: 188491
  year: 2021
  ident: CR157
  article-title: Non-coding RNAs and potential therapeutic targeting in cancer
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2020.188491
– volume: 99
  start-page: 129
  year: 2016
  end-page: 37
  ident: CR88
  article-title: The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2016.01.022
– volume: 353
  start-page: aaf5573
  year: 2016
  ident: CR51
  article-title: C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
  publication-title: Science
  doi: 10.1126/science.aaf5573
– volume: 16
  start-page: 181
  year: 2017
  end-page: 202
  ident: CR54
  article-title: Aptamers as targeted therapeutics: current potential and challenges
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.199
– volume: 20
  start-page: 497
  year: 2017
  end-page: 9
  ident: CR18
  article-title: Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy
  publication-title: Nat Neurosci
  doi: 10.1038/nn.4508
– volume: 3
  start-page: 311
  year: 2012
  end-page: 30
  ident: CR37
  article-title: Posttranscriptional upregulation by microRNAs
  publication-title: Wiley Interdiscip Rev RNA
  doi: 10.1002/wrna.121
– volume: 184
  start-page: 6053
  year: 2010
  end-page: 9
  ident: CR39
  article-title: MicroRNA-466l upregulates IL-10 expression in TLR-triggered macrophages by antagonizing RNA-binding protein tristetraprolin-mediated IL-10 mRNA degradation
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0902308
– volume: 32
  start-page: 297
  year: 2018
  end-page: 309
  ident: CR110
  article-title: Spherical nucleic acid nanoparticles: therapeutic potential
  publication-title: BioDrugs
  doi: 10.1007/s40259-018-0290-5
– volume: 586
  start-page: 567
  year: 2020
  end-page: 71
  ident: CR149
  article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
  publication-title: Nature.
  doi: 10.1038/s41586-020-2622-0
– volume: 50
  start-page: 2224
  year: 2021
  end-page: 43
  ident: CR5
  article-title: Targeting RNA with small molecules: from fundamental principles towards the clinic
  publication-title: Chem Soc Rev
  doi: 10.1039/D0CS01261K
– volume: 11
  start-page: 518
  year: 2020
  end-page: 24
  ident: CR160
  article-title: Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver
  publication-title: Protein Cell
  doi: 10.1007/s13238-020-00700-2
– volume: 78
  start-page: 1224
  year: 2020
  end-page: 36.e5
  ident: CR36
  article-title: A mechanism for microRNA arm switching regulated by uridylation
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2020.04.030
– volume: 45
  start-page: 10969
  year: 2017
  end-page: 77
  ident: CR133
  article-title: Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx818
– volume: 6
  start-page: 659
  year: 2009
  end-page: 68
  ident: CR101
  article-title: The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic
  publication-title: Mol Pharm
  doi: 10.1021/mp900015y
– volume: 24
  start-page: 374
  year: 2014
  end-page: 87
  ident: CR65
  article-title: Phosphorothioates, essential components of therapeutic oligonucleotides
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2014.0506
– volume: 80
  start-page: 335
  year: 2020
  end-page: 9
  ident: CR134
  article-title: Givosiran: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-020-01269-0
– volume: 20
  year: 2021
  ident: CR58
  article-title: mRNA therapeutics in cancer immunotherapy
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01348-0
– volume: 16
  start-page: 1833
  year: 2008
  end-page: 40
  ident: CR75
  article-title: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability
  publication-title: Mol Ther
  doi: 10.1038/mt.2008.200
– volume: 8
  start-page: 173
  year: 2007
  end-page: 84
  ident: CR27
  article-title: Strategies for silencing human disease using RNA interference
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg2006
– volume: 65
  start-page: 391
  year: 2013
  end-page: 7
  ident: CR105
  article-title: Exosomes for targeted siRNA delivery across biological barriers
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2012.08.008
– volume: 3
  start-page: e169
  year: 2014
  ident: CR55
  article-title: Cell-type-specific, Aptamer-functionalized agents for targeted disease therapy
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2014.21
– volume: 185
  start-page: 1728
  year: 2022
  end-page: 44.e16
  ident: CR156
  article-title: Circular RNA vaccines against SARS-CoV-2 and emerging variants
  publication-title: Cell
  doi: 10.1016/j.cell.2022.03.044
– volume: 28
  start-page: 367
  year: 2018
  end-page: 73
  ident: CR80
  article-title: CRISPR RNAs trigger innate immune responses in human cells
  publication-title: Genome Res
  doi: 10.1101/gr.231936.117
– volume: 80
  start-page: 1027
  year: 2020
  end-page: 31
  ident: CR123
  article-title: Viltolarsen: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-020-01339-3
– volume: 25
  start-page: 1066
  year: 2019
  end-page: 79
  ident: CR107
  article-title: Applications of spherical nucleic acid nanoparticles as delivery systems
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2019.08.012
– volume: 3
  start-page: 166
  year: 2007
  end-page: 73
  ident: CR42
  article-title: Activating gene expression in mammalian cells with promoter-targeted duplex RNAs
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio860
– volume: 19
  start-page: 112
  year: 2020
  end-page: 29
  ident: CR15
  article-title: Targeting mRNA processing as an anticancer strategy
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0042-3
– volume: 21
  start-page: 48
  year: 2019
  ident: CR120
  article-title: Lomitapide and mipomersen-inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis
  publication-title: Curr Atheroscler Rep
  doi: 10.1007/s11883-019-0809-3
– volume: 32
  start-page: 297
  year: 2018
  ident: 5075_CR110
  publication-title: BioDrugs
  doi: 10.1007/s40259-018-0290-5
– volume: 12
  start-page: e1627
  year: 2021
  ident: 5075_CR35
  publication-title: Wiley Interdiscip Rev Rna.
  doi: 10.1002/wrna.1627
– volume: 24
  start-page: 374
  year: 2014
  ident: 5075_CR65
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2014.0506
– volume: 185
  start-page: 1728
  year: 2022
  ident: 5075_CR156
  publication-title: Cell
  doi: 10.1016/j.cell.2022.03.044
– volume: 495
  start-page: 384
  year: 2013
  ident: 5075_CR153
  publication-title: Nature.
  doi: 10.1038/nature11993
– volume: 20
  start-page: 817
  year: 2021
  ident: 5075_CR57
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00283-5
– volume: 15
  start-page: 188
  year: 2001
  ident: 5075_CR30
  publication-title: Genes Dev
  doi: 10.1101/gad.862301
– volume: 156
  start-page: 172
  year: 2018
  ident: 5075_CR76
  publication-title: Biomaterials.
  doi: 10.1016/j.biomaterials.2017.11.034
– volume: 20
  year: 2021
  ident: 5075_CR151
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01335-5
– volume: 3
  start-page: 166
  year: 2007
  ident: 5075_CR42
  publication-title: Nat Chem Biol
  doi: 10.1038/nchembio860
– volume: 3
  start-page: e169
  year: 2014
  ident: 5075_CR55
  publication-title: Mol Ther Nucleic Acids
  doi: 10.1038/mtna.2014.21
– volume: 87
  start-page: 68
  year: 2015
  ident: 5075_CR86
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2015.02.007
– volume: 11
  start-page: 1721
  year: 2014
  ident: 5075_CR113
  publication-title: Mol Pharm
  doi: 10.1021/mp500047b
– volume: 20
  start-page: 427
  year: 2021
  ident: 5075_CR11
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00162-z
– volume: 464
  start-page: 1067
  year: 2010
  ident: 5075_CR100
  publication-title: Nature.
  doi: 10.1038/nature08956
– volume: 45
  start-page: 10969
  year: 2017
  ident: 5075_CR133
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx818
– volume: 355
  start-page: 850
  year: 1992
  ident: 5075_CR53
  publication-title: Nature.
  doi: 10.1038/355850a0
– volume: 11
  start-page: 518
  year: 2020
  ident: 5075_CR160
  publication-title: Protein Cell
  doi: 10.1007/s13238-020-00700-2
– volume: 80
  start-page: 1027
  year: 2020
  ident: 5075_CR123
  publication-title: Drugs
  doi: 10.1007/s40265-020-01339-3
– volume: 35
  start-page: 222
  year: 2017
  ident: 5075_CR59
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3802
– volume: 23
  start-page: 1380
  year: 2015
  ident: 5075_CR143
  publication-title: Mol Ther
  doi: 10.1038/mt.2015.71
– volume: 37
  start-page: 708
  year: 2019
  ident: 5075_CR9
  publication-title: Biotechnol Adv
  doi: 10.1016/j.biotechadv.2019.03.016
– volume: 24
  start-page: 430
  year: 2016
  ident: 5075_CR145
  publication-title: Mol Ther
  doi: 10.1038/mt.2016.10
– volume: 812
  start-page: 138
  year: 2014
  ident: 5075_CR84
  publication-title: Anal Chim Acta
  doi: 10.1016/j.aca.2013.12.023
– volume: 54
  start-page: 12029
  year: 2015
  ident: 5075_CR114
  publication-title: Angew Chem Int Ed Engl
  doi: 10.1002/anie.201506030
– volume: 103
  start-page: 85s
  issue: 5 Suppl
  year: 1994
  ident: 5075_CR14
  publication-title: J Investig Dermatol
  doi: 10.1038/jid.1994.15
– volume: 13
  start-page: 875
  year: 2013
  ident: 5075_CR67
  publication-title: Expert Opin Biol Ther
  doi: 10.1517/14712598.2013.774366
– volume: 40
  start-page: 2004
  year: 1996
  ident: 5075_CR119
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.40.9.2004
– volume: 21
  start-page: 48
  year: 2019
  ident: 5075_CR120
  publication-title: Curr Atheroscler Rep
  doi: 10.1007/s11883-019-0809-3
– volume: 20
  start-page: 490
  year: 2019
  ident: 5075_CR46
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-019-0131-5
– volume: 21
  start-page: 251
  year: 2013
  ident: 5075_CR102
  publication-title: Mol Ther
  doi: 10.1038/mt.2012.202
– volume: 39
  start-page: 982
  year: 2018
  ident: 5075_CR16
  publication-title: Trends Pharm Sci
  doi: 10.1016/j.tips.2018.09.001
– volume: 87
  start-page: 108
  year: 2015
  ident: 5075_CR87
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2015.01.007
– volume: 38
  start-page: 53
  year: 2019
  ident: 5075_CR139
  publication-title: J Exp Clin Cancer Res
  doi: 10.1186/s13046-019-1059-5
– volume: 4
  start-page: 791
  year: 2013
  ident: 5075_CR70
  publication-title: Ther Deliv
  doi: 10.4155/tde.13.47
– volume: 99
  start-page: 129
  year: 2016
  ident: 5075_CR88
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2016.01.022
– volume: 37
  start-page: 107
  year: 2018
  ident: 5075_CR62
  publication-title: Cancer Metastasis Rev
  doi: 10.1007/s10555-017-9717-6
– volume: 144
  start-page: 90
  year: 2019
  ident: 5075_CR166
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2019.08.004
– volume: 4
  start-page: 1591
  year: 2011
  ident: 5075_CR97
  publication-title: Pharmaceuticals
  doi: 10.3390/ph4121591
– volume: 381
  start-page: 1644
  year: 2019
  ident: 5075_CR125
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1813279
– volume: 353
  start-page: aaf5573
  year: 2016
  ident: 5075_CR51
  publication-title: Science
  doi: 10.1126/science.aaf5573
– volume: 9
  year: 2018
  ident: 5075_CR81
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-03927-0
– ident: 5075_CR83
  doi: 10.1002/0471142700.nc0446s46
– volume: 28
  start-page: 1506
  year: 2020
  ident: 5075_CR154
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.04.006
– volume: 19
  start-page: 112
  year: 2020
  ident: 5075_CR15
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0042-3
– volume: 318
  start-page: 271
  year: 2007
  ident: 5075_CR26
  publication-title: Science.
  doi: 10.1126/science.1147535
– volume: 42
  start-page: 448
  year: 2021
  ident: 5075_CR92
  publication-title: Trends Pharm Sci
  doi: 10.1016/j.tips.2021.03.002
– volume: 34
  start-page: 1213
  year: 2016
  ident: 5075_CR132
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1216-1213
– volume: 18
  start-page: 1683
  year: 2017
  ident: 5075_CR82
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms18081683
– volume: 7
  start-page: 389
  year: 2012
  ident: 5075_CR112
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2012.73
– volume: 21
  start-page: 2224
  year: 2021
  ident: 5075_CR96
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.0c05039
– volume: 7
  start-page: eabf4398
  year: 2021
  ident: 5075_CR94
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abf4398
– volume: 50
  start-page: 2224
  year: 2021
  ident: 5075_CR5
  publication-title: Chem Soc Rev
  doi: 10.1039/D0CS01261K
– volume: 27
  start-page: 714
  year: 2018
  ident: 5075_CR4
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2018.03.004
– volume: 116
  start-page: 281
  year: 2004
  ident: 5075_CR34
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
– volume: 1875
  start-page: 188491
  year: 2021
  ident: 5075_CR157
  publication-title: Biochim Biophys Acta Rev Cancer
  doi: 10.1016/j.bbcan.2020.188491
– volume: 13
  start-page: 759
  year: 2014
  ident: 5075_CR7
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4278
– volume: 29
  start-page: 1293
  year: 2001
  ident: 5075_CR22
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/29.6.1293
– volume: 16
  start-page: 203
  year: 2017
  ident: 5075_CR40
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.246
– volume: 18
  start-page: 421
  year: 2019
  ident: 5075_CR68
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-019-0017-4
– volume: 27
  start-page: 67
  year: 2017
  ident: 5075_CR121
  publication-title: Nucleic Acid Ther
  doi: 10.1089/nat.2017.0665
– volume: 16
  start-page: 167
  year: 2017
  ident: 5075_CR158
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.117
– volume: 81
  start-page: 875
  year: 2021
  ident: 5075_CR124
  publication-title: Drugs
  doi: 10.1007/s40265-021-01512-2
– volume: 73
  start-page: 329
  year: 2022
  ident: 5075_CR74
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2021.09.016
– volume: 44
  start-page: 2274
  year: 2016
  ident: 5075_CR43
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw076
– volume: 358
  start-page: 1019
  year: 2017
  ident: 5075_CR52
  publication-title: Science.
  doi: 10.1126/science.aaq0180
– volume: 15
  start-page: 285
  year: 2009
  ident: 5075_CR128
  publication-title: Nat Med
  doi: 10.1038/nm.1932
– volume: 25
  start-page: 229
  year: 2019
  ident: 5075_CR144
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0327-9
– volume: 5
  start-page: 1642
  year: 2013
  ident: 5075_CR8
  publication-title: EMBO Mol Med
  doi: 10.1002/emmm.201202287
– volume: 78
  start-page: 1224
  year: 2020
  ident: 5075_CR36
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2020.04.030
– volume: 81
  start-page: 277
  year: 2021
  ident: 5075_CR135
  publication-title: Drugs
  doi: 10.1007/s40265-020-01463-0
– volume: 457
  start-page: 426
  year: 2009
  ident: 5075_CR31
  publication-title: Nature.
  doi: 10.1038/nature07758
– volume: 378
  start-page: 546
  year: 2011
  ident: 5075_CR17
  publication-title: Lancet.
  doi: 10.1016/S0140-6736(11)61028-3
– volume: 184
  start-page: 6053
  year: 2010
  ident: 5075_CR39
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0902308
– volume: 28
  start-page: 367
  year: 2018
  ident: 5075_CR80
  publication-title: Genome Res
  doi: 10.1101/gr.231936.117
– volume: 13
  start-page: 549
  year: 2009
  ident: 5075_CR6
  publication-title: Curr Opin Chem Biol
  doi: 10.1016/j.cbpa.2009.08.003
– volume: 3
  start-page: 235
  year: 2001
  ident: 5075_CR71
  publication-title: Curr Opin Mol Ther
– volume: 10
  start-page: 551
  year: 2010
  ident: 5075_CR13
  publication-title: Curr Opin Pharm
  doi: 10.1016/j.coph.2010.07.002
– volume: 16
  start-page: 181
  year: 2017
  ident: 5075_CR54
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2016.199
– volume: 9
  start-page: 654
  year: 2007
  ident: 5075_CR106
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1596
– volume: 367
  start-page: eaau6977
  year: 2020
  ident: 5075_CR104
  publication-title: Science
  doi: 10.1126/science.aau6977
– volume: 586
  start-page: 567
  year: 2020
  ident: 5075_CR149
  publication-title: Nature.
  doi: 10.1038/s41586-020-2622-0
– volume: 247
  start-page: 1465
  year: 1990
  ident: 5075_CR56
  publication-title: Science.
  doi: 10.1126/science.1690918
– volume: 17
  start-page: 547
  year: 2018
  ident: 5075_CR170
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2018.93
– volume: 5
  start-page: 16014
  year: 2016
  ident: 5075_CR85
  publication-title: Mol Ther Methods Clin Dev
  doi: 10.1038/mtm.2016.14
– volume: 53
  start-page: 453
  year: 2015
  ident: 5075_CR115
  publication-title: Biomaterials.
  doi: 10.1016/j.biomaterials.2015.02.099
– volume: 26
  start-page: 3936
  year: 2020
  ident: 5075_CR140
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-0414
– volume: 20
  year: 2021
  ident: 5075_CR150
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01339-1
– volume: 6
  start-page: 763
  year: 2011
  ident: 5075_CR117
  publication-title: Nat Nanotechnol
  doi: 10.1038/nnano.2011.187
– volume: 33
  start-page: 985
  year: 2015
  ident: 5075_CR78
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3290
– volume: 6
  start-page: 24
  year: 2005
  ident: 5075_CR33
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg1500
– volume: 110
  start-page: 20723
  year: 2013
  ident: 5075_CR136
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1314307110
– volume: 19
  start-page: 611
  year: 2018
  ident: 5075_CR141
  publication-title: Curr Pharm Biotechnol
  doi: 10.2174/1389201019666180611093428
– volume: 110
  start-page: 7625
  year: 2013
  ident: 5075_CR108
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1305804110
– volume: 25
  start-page: 71
  year: 2017
  ident: 5075_CR131
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2016.10.019
– volume: 57
  start-page: 375
  year: 1999
  ident: 5075_CR118
  publication-title: Drugs
  doi: 10.2165/00003495-199957030-00010
– volume: 118
  start-page: 4098
  year: 2012
  ident: 5075_CR127
  publication-title: Cancer.
  doi: 10.1002/cncr.26730
– volume: 80
  start-page: 335
  year: 2020
  ident: 5075_CR134
  publication-title: Drugs
  doi: 10.1007/s40265-020-01269-0
– volume: 8
  start-page: 1616
  year: 2011
  ident: 5075_CR66
  publication-title: Chem Biodivers
  doi: 10.1002/cbdv.201100081
– volume: 5
  start-page: 209ra152
  year: 2013
  ident: 5075_CR109
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.3006839
– volume: 43
  start-page: 3857
  year: 2015
  ident: 5075_CR165
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkv228
– volume: 68
  start-page: 904
  year: 2016
  ident: 5075_CR98
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2016.07.066
– volume: 81
  start-page: 495
  year: 2021
  ident: 5075_CR147
  publication-title: Drugs
  doi: 10.1007/s40265-021-01480-7
– volume: 27
  start-page: 1547
  year: 1999
  ident: 5075_CR21
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/27.6.1547
– volume: 20
  year: 2021
  ident: 5075_CR73
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01311-z
– volume: 6
  start-page: 5931
  year: 2012
  ident: 5075_CR116
  publication-title: ACS Nano
  doi: 10.1021/nn300727j
– volume: 516
  start-page: 263
  year: 2014
  ident: 5075_CR48
  publication-title: Nature.
  doi: 10.1038/nature13769
– volume: 168
  start-page: 246
  year: 2021
  ident: 5075_CR77
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.10.014
– volume: 201
  start-page: 41
  year: 2015
  ident: 5075_CR103
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2015.01.017
– volume: 62
  start-page: 12
  year: 2010
  ident: 5075_CR99
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2009.08.004
– volume: 3
  start-page: 311
  year: 2012
  ident: 5075_CR37
  publication-title: Wiley Interdiscip Rev RNA
  doi: 10.1002/wrna.121
– volume: 24
  start-page: 345
  year: 2019
  ident: 5075_CR38
  publication-title: Mol Psychiatry
  doi: 10.1038/s41380-018-0266-3
– volume: 34
  start-page: 1339
  year: 2017
  ident: 5075_CR137
  publication-title: Pharm Res
  doi: 10.1007/s11095-017-2134-2
– volume: 16
  start-page: 813
  year: 2017
  ident: 5075_CR168
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2017.239
– volume: 8
  start-page: 173
  year: 2007
  ident: 5075_CR27
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg2006
– volume: 20
  year: 2021
  ident: 5075_CR58
  publication-title: Mol Cancer
  doi: 10.1186/s12943-021-01348-0
– volume: 33
  start-page: 586
  year: 2015
  ident: 5075_CR111
  publication-title: Trends Biotechnol
  doi: 10.1016/j.tibtech.2015.08.001
– volume: 367
  start-page: 20
  year: 2006
  ident: 5075_CR126
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2005.11.023
– volume: 59
  start-page: 9645
  year: 2016
  ident: 5075_CR64
  publication-title: J Med Chem
  doi: 10.1021/acs.jmedchem.6b00551
– volume: 31
  start-page: 638
  year: 2013
  ident: 5075_CR91
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2612
– volume: 22
  start-page: 9168
  year: 2021
  ident: 5075_CR142
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22179168
– volume: 80
  start-page: 1853
  year: 2020
  ident: 5075_CR169
  publication-title: Drugs
  doi: 10.1007/s40265-020-01410-z
– volume: 30
  start-page: 1911
  year: 2002
  ident: 5075_CR69
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/30.9.1911
– volume: 20
  start-page: 629
  year: 2021
  ident: 5075_CR159
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/s41573-021-00219-z
– volume: 346
  start-page: 1258096
  year: 2014
  ident: 5075_CR47
  publication-title: Science.
  doi: 10.1126/science.1258096
– volume: 35
  start-page: 238
  year: 2017
  ident: 5075_CR60
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3765
– volume: 495
  start-page: 333
  year: 2013
  ident: 5075_CR152
  publication-title: Nature.
  doi: 10.1038/nature11928
– volume: 11
  start-page: e1004656
  year: 2015
  ident: 5075_CR162
  publication-title: PLoS Comput Biol
  doi: 10.1371/journal.pcbi.1004656
– volume: 42
  start-page: 217
  year: 2013
  ident: 5075_CR32
  publication-title: Annu Rev Biophys
  doi: 10.1146/annurev-biophys-083012-130404
– volume: 3
  start-page: 154
  year: 2012
  ident: 5075_CR61
  publication-title: Front Genet
  doi: 10.3389/fgene.2012.00154
– volume: 441
  start-page: 537
  year: 2006
  ident: 5075_CR163
  publication-title: Nature.
  doi: 10.1038/nature04791
– volume: 34
  start-page: 875
  year: 2016
  ident: 5075_CR23
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3589
– volume: 13
  start-page: 622
  year: 2014
  ident: 5075_CR25
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4359
– volume: 75
  start-page: 280
  year: 1978
  ident: 5075_CR1
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.75.1.280
– volume: 25
  start-page: 1066
  year: 2019
  ident: 5075_CR107
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2019.08.012
– volume: 103
  start-page: 17337
  year: 2006
  ident: 5075_CR41
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0607015103
– volume: 7
  start-page: e32724
  year: 2018
  ident: 5075_CR49
  publication-title: Elife
  doi: 10.7554/eLife.32724
– volume: 26
  start-page: 320
  year: 2016
  ident: 5075_CR44
  publication-title: Cell Res
  doi: 10.1038/cr.2016.22
– volume: 159
  start-page: 344
  year: 2020
  ident: 5075_CR90
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.06.026
– volume: 288
  start-page: 343
  year: 2005
  ident: 5075_CR72
  publication-title: Methods Mol Biol
– volume: 16
  start-page: 1833
  year: 2008
  ident: 5075_CR75
  publication-title: Mol Ther
  doi: 10.1038/mt.2008.200
– volume: 46
  start-page: 792
  year: 2018
  ident: 5075_CR79
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx1199
– volume: 384
  start-page: 403
  year: 2021
  ident: 5075_CR148
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2035389
– volume: 379
  start-page: 22
  year: 2018
  ident: 5075_CR130
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1716793
– volume: 35
  start-page: 687
  year: 2007
  ident: 5075_CR164
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkl1071
– volume: 98
  start-page: 9742
  year: 2001
  ident: 5075_CR29
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.171251798
– volume: 31
  start-page: e1902798
  year: 2019
  ident: 5075_CR167
  publication-title: Adv Mater
  doi: 10.1002/adma.201902798
– volume: 8
  start-page: 1182
  year: 2017
  ident: 5075_CR138
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.01182
– volume: 24
  start-page: 4229
  year: 2019
  ident: 5075_CR10
  publication-title: Molecules.
  doi: 10.3390/molecules24234229
– volume: 26
  start-page: 6530
  year: 2021
  ident: 5075_CR45
  publication-title: Molecules
  doi: 10.3390/molecules26216530
– volume: 20
  start-page: 5167
  year: 2020
  ident: 5075_CR93
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.0c00596
– volume: 15
  start-page: 313
  year: 2020
  ident: 5075_CR95
  publication-title: Nat Nanotechnol
  doi: 10.1038/s41565-020-0669-6
– volume: 45
  start-page: 9528
  year: 2017
  ident: 5075_CR24
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkx632
– volume: 391
  start-page: 806
  year: 1998
  ident: 5075_CR28
  publication-title: Nature.
  doi: 10.1038/35888
– volume: 42
  start-page: 5871
  year: 2014
  ident: 5075_CR19
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gku184
– volume: 89
  start-page: 652
  year: 2000
  ident: 5075_CR89
  publication-title: J Pharm Sci
  doi: 10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H
– volume: 25
  start-page: 2075
  year: 2017
  ident: 5075_CR12
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2017.06.002
– volume: 411
  start-page: 494
  year: 2001
  ident: 5075_CR2
  publication-title: Nature
  doi: 10.1038/35078107
– volume: 20
  start-page: 497
  year: 2017
  ident: 5075_CR18
  publication-title: Nat Neurosci
  doi: 10.1038/nn.4508
– volume: 65
  start-page: 391
  year: 2013
  ident: 5075_CR105
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2012.08.008
– volume: 5
  start-page: 123
  year: 2006
  ident: 5075_CR146
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1955
– volume: 7
  start-page: 835
  year: 2020
  ident: 5075_CR161
  publication-title: Natl Sci Rev
  doi: 10.1093/nsr/nwaa033
– volume: 5
  start-page: 2715
  year: 2016
  ident: 5075_CR63
  publication-title: Adv Health Mater
  doi: 10.1002/adhm.201600418
– volume: 6
  start-page: 659
  year: 2009
  ident: 5075_CR101
  publication-title: Mol Pharm
  doi: 10.1021/mp900015y
– volume: 379
  start-page: 11
  year: 2018
  ident: 5075_CR129
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1716153
– volume: 173
  start-page: 665
  year: 2018
  ident: 5075_CR50
  publication-title: Cell
  doi: 10.1016/j.cell.2018.02.033
– volume: 82
  start-page: 420
  year: 2022
  ident: 5075_CR155
  publication-title: Mol Cell
  doi: 10.1016/j.molcel.2021.11.019
– volume: 82
  start-page: 144
  year: 1985
  ident: 5075_CR20
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.82.1.144
– volume: 80
  start-page: 329
  year: 2020
  ident: 5075_CR122
  publication-title: Drugs
  doi: 10.1007/s40265-020-01267-2
– volume: 19
  start-page: 441
  year: 2020
  ident: 5075_CR3
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/d41573-020-00078-0
SSID ssj0000330256
Score 2.7005856
SecondaryResourceType review_article
Snippet The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on hitherto...
Abstract The growing understanding of RNA functions and their crucial roles in diseases promotes the application of various RNAs to selectively function on...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 644
SubjectTerms 38/71
38/90
42/89
45/91
631/154/152
631/61/391/1914
64/60
Antibodies
Binding sites
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Culture
Clinical trials
Disease
Drugs
Enzymes
Gene expression
Genomes
Immunology
Life Sciences
Medical research
MicroRNAs
Proteins
Review
Review Article
Ribonucleic acid
RNA
RNA Interference
RNA, Small Interfering - genetics
Therapeutic targets
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7BFqReeFMCBQWJG1hdx05s91K1qBWnVVWB1Jvl-AGVULZsdpH494wdb8oC7aW3KHbix8zYMx7PNwDvrGiUEiEQLmSIITmKGBocMUYwXA6dYa5NySbEbCbPz9VpPnDr87XK9ZqYFmo3t_GMfK9qVAz0bRQ9uPxBYtao6F3NKTTuwlZEKuMT2Do6np2ejacsUzTXcVPP0TJTJvd6TnmM20EbbIq6UE2qjR0pAff_T9v899LkX57TtCGdPLztUB7Bg6yKlocD7zyGO757AveH5JS_nkJ1NjskcZNz5R9BWv1-aboy3vuMjeCzK7H1FK-56p_Bl5Pjzx8_kZxhgVg0XJbEOWeptdwxK5T0tLWOVya0NRetrx1OkHFoT3AeYo4jYbxwbeVF4MFKTr1kz2HSzTv_AkpjA2cJbaa1vHWibQz1-Cgi-oC3sgC6nmVtM_x4zILxXSc3OJN6oIxGyuhEGV0V8H785nIA37ix9lEk3lgzAmenF_PFV53lUNeOSReVpNop1J0M6ofMU9QU2NTKUNcF7K5pprM09_qKYAW8HYtRDqNzxXR-vhrqCEFrqQrYGThl7Amr0SytaFOA2OChja5ulnQX3xLWt2Ko0jP854c1t1116_qpeHnzKF7BdpUEQJCK7cJkuVj513DP_lxe9Is3WYZ-AyOEJBI
  priority: 102
  providerName: ProQuest
Title RNA-based therapeutics: an overview and prospectus
URI https://link.springer.com/article/10.1038/s41419-022-05075-2
https://www.ncbi.nlm.nih.gov/pubmed/35871216
https://www.proquest.com/docview/2693185691
https://www.proquest.com/docview/2693771589
https://pubmed.ncbi.nlm.nih.gov/PMC9308039
https://doaj.org/article/5d38d50915d9431a8393e1cee30c8f55
Volume 13
WOSCitedRecordID wos000830022100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: M7P
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: 7X7
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: BENPR
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Publicly Available Content Database
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: PIMPY
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2041-4889
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000330256
  issn: 2041-4889
  databaseCode: M2P
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_0TsEX8dvquVTwTcttPtpJfLuTO_ThluVQWJ9Cmg88kJ5cdwX_eydpd93188WXEJq0TCeTzAyT-Q3AC4eN1hhjJVHFlJKjK8uir6xFQceht8K3udgEzmZqsdDzrVJf6U7YAA88MO6w9kL5pNVqr0nZWVLoIjA62sXUqVhn9FKyeracqXwGk5tOynzMkpkKddhLJlO-DvleU7KB6orvaKIM2P87K_PXy5I_RUyzIjq9A7dHC7I8Gii_C9dCdw9uDjUlv90Hfj47qpJu8uVWblX_urRdma5rplAA9X1JNOQ0y1X_AD6cnrx_87YaCyNUjvyNZeW9d8w56YVDrQJrnZfcxraW2Iba0_9ZT26AlDGVJkIb0Lc8YJTRKcmCEg9hr7vswmMorYtSZJCY1snWY9tYFqiLCTQgOFUAWzPJuBE1PBWv-Gxy9FooMzDWEGNNZqzhBbzcvPNlwMz46-zjxPvNzIR3nR-QFJhRCsy_pKCAg_XKmXET9oY3OuWGN5oV8HwzTNsnxURsFy5XwxxEVitdwKNhoTeUiJq8Sc6aAnBHBHZI3R3pLj5liG4tSCYFffPVWlh-kPVnVjz5H6x4Crd4lnKsuDiAveXVKjyDG-7r8qK_msB1XGBu1QT2j09m8_NJ3jrUnvF5apHa_fm7s_nH7_9aGvo
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qBQQXdkqgQJDgBFbjLXaQECpL1aplhFCR5mYcL7QSypTJDKh_it-I7SRThqW3HrhZsWN5-fz8PdvvPYDHRpRVJbxHTEgfTXIqpLG3SGtBgzi0mto6BZsQo5Ecj6v3K_BjsIWJzyoHmZgEtZ2YeEa-QcoqGvqWFX559BXFqFHxdnUIodHBYtcdfw8qW_ti502Y3yeEbL3df72N-qgCyASyPkPWWoONYZYaUUmHa2MZ0b7mTNSO24IX2gYOzZiPcX2EdsLWxAnPvJEMO0lDvefgfJDjIj4hE2OxONMpKI0UorfNKajcaBlm0UooaHyhYsERWdr_UpiAv3HbP59o_nZPm7a_rav_28Bdgys90c43u5VxHVZccwMudqE3j28C-TDaRHELt_kvJmjt81w3eXzVGjsV0jYPvU3WqPP2Fnw8kwbfhtVm0rg7kGvjGU2-dGrDaivqUmMXkiL6VnBGZoCHWVWmd64eY3x8UemSn0rVIUEFJKiEBEUyeLr456hzLXJq6VcRLIuS0S14-jCZfla9lFHcUmkjBeS2CsxQB_ZLHQ48iBZGes4zWB8wonpZ1aoTgGTwaJEdpEy8OtKNm8y7MkJgLqsM1jpkLlpCeVC6CS4zEEuYXWrqck5zeJA8mVc0KCw01PlsQPdJs_49FHdP78VDuLS9_25P7e2Mdu_BZZIWn0CErsPqbDp39-GC-TY7bKcP0urN4dNZo_4neL6D5w
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qZREX9iVQIEhwotHEW-wgIVQoI6rCaIRA6s04XtpKKFMmM6D-NX4dtrOUYemtB25W7FhePj9_z_Z7D-CJ5kVZcucyyoULJjllppAzmVKceHFoFDFVDDbBJxOxt1dO1-BHbwsTnlX2MjEKajPT4Yx8hIsyGPoWJRq57lnEdHv88uhrFiJIhZvWPpxGC5Fde_zdq2_Ni51tP9dPMR6_-fj6bdZFGMi0J-6LzBijkdbUEM1LYVGlDcXKVYzyyjKTs1wZz6cpdSHGD1eWmwpb7qjTgiIriK_3HJznlLGwut7j6XC-kxMS6ERnp5MTMWooosFiyGt_vmLOMryyF8aQAX_juX8-1_ztzjZuheOr__MgXoMrHQFPt9oVcx3WbH0DLrYhOY9vAv4w2crC1m7SX0zTmuepqtPw2jV00KdN6nserVSXzS34dCYNvg3r9ay2dyFV2lESfexUmlaGV4VC1id58LlgtUgA9TMsded0PcT--CLj5T8RskWF9KiQERUSJ_Bs-OeodTlyaulXAThDyeAuPH6YzfdlJ30kM0SYQA2ZKT1jVJ4VE4s8PyK5Fo6xBDZ6vMhOhjXyBCwJPB6yvfQJV0qqtrNlW4ZzxESZwJ0WpUNLCPPKOEZFAnwFvytNXc2pDw-ih_OSeEWG-Do3e6SfNOvfQ3Hv9F48gkse7PLdzmT3PlzGcR3yDJMNWF_Ml_YBXNDfFofN_GFcyCl8PmvQ_wRhooy0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=RNA-based+therapeutics%3A+an+overview+and+prospectus&rft.jtitle=Cell+death+%26+disease&rft.au=Yiran+Zhu&rft.au=Liyuan+Zhu&rft.au=Xian+Wang&rft.au=Hongchuan+Jin&rft.date=2022-07-23&rft.pub=Nature+Publishing+Group&rft.eissn=2041-4889&rft.volume=13&rft.issue=7&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1038%2Fs41419-022-05075-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_5d38d50915d9431a8393e1cee30c8f55
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-4889&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-4889&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-4889&client=summon